Amedeo Smart

Free Medical Literature Service

 

Amedeo

COVID-19
  Free Subscription

Articles published in
Lancet Infect Dis
    May 2024
  1. VENKATESAN P
    Tobias Welte.
    Lancet Infect Dis. 2024;24:457.
    >> Share

  2. MOODY J
    On the frontline during the COVID-19 pandemic.
    Lancet Infect Dis. 2024;24:464.
    >> Share

  3. KAZI F, Mushtaq A
    Nuria Izquierdo-Useros-fighting the good fight.
    Lancet Infect Dis. 2024;24:458.
    >> Share

  4. DE AMBROGI M
    A summer cold.
    Lancet Infect Dis. 2024;24:461.
    >> Share

  5. LIN DY, Huang S, Milinovich A, Duggal A, et al
    Effectiveness of XBB.1.5 vaccines and antiviral drugs against severe outcomes of omicron infection in the USA.
    Lancet Infect Dis. 2024;24:e278-e280.
    >> Share

  6. KOCHER K, Moosmann C, Drost F, Schulein C, et al
    Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual.
    Lancet Infect Dis. 2024;24:e272-e274.
    >> Share

  7. KEDDY KH, Tadesse BT
    Inaccessible: health, wealth, governance, and equity in low-income and middle-income countries.
    Lancet Infect Dis. 2024;24:444-445.
    >> Share

    April 2024
  8. WONGNAK P, Schilling WHK, Jittamala P, Boyd S, et al
    Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV).
    Lancet Infect Dis. 2024 Apr 24:S1473-3099(24)00183.
    >> Share

  9. VISSER LG
    Identifying efficacious SARS-CoV-2 antivirals in a changing immune landscape.
    Lancet Infect Dis. 2024 Apr 24:S1473-3099(24)00254.
    >> Share

  10. BUONSENSO D, Tantisira KG
    Long COVID and SARS-CoV-2 persistence: new answers, more questions.
    Lancet Infect Dis. 2024 Apr 22:S1473-3099(24)00216.
    >> Share

  11. ZUO W, He D, Liang C, Du S, et al
    The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China.
    Lancet Infect Dis. 2024 Apr 22:S1473-3099(24)00171.
    >> Share

  12. JIN SL, Kolis J, Parker J, Proctor DA, et al
    Social histories of public health misinformation and infodemics: case studies of four pandemics.
    Lancet Infect Dis. 2024 Apr 19:S1473-3099(24)00105.
    >> Share


  13. Global burden associated with 85 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.
    Lancet Infect Dis. 2024 Apr 16:S1473-3099(24)00158.
    >> Share


  14. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.
    Lancet Infect Dis. 2024 Apr 15:S1473-3099(24)00176.
    >> Share

  15. PELUSO MJ, Swank ZN, Goldberg SA, Lu S, et al
    Plasma-based antigen persistence in the post-acute phase of COVID-19.
    Lancet Infect Dis. 2024 Apr 8:S1473-3099(24)00211.
    >> Share

  16. DE MENEZES NEVES PDM, Mohrbacher S, Lobato Vasques I, Barreira Cavalcante L, et al
    Renal infarction secondary to Aspergillus spp. embolism following COVID-19.
    Lancet Infect Dis. 2024;24:e266-e267.
    >> Share

    March 2024
  17. LARIVIERE Y, Matuvanga TZ, Osang'ir BI, Milolo S, et al
    Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised
    Lancet Infect Dis. 2024 Mar 26:S1473-3099(24)00058.
    >> Share

  18. WANNIGAMA DL, Amarasiri M, Phattharapornjaroen P, Hurst C, et al
    Increased faecal shedding in SARS-CoV-2 variants BA.2.86 and JN.1.
    Lancet Infect Dis. 2024 Mar 21:S1473-3099(24)00155.
    >> Share

  19. DIXIT A, Bennett R, Ali K, Griffin C, et al
    Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.
    Lancet Infect Dis. 2024 Mar 19:S1473-3099(24)00101.
    >> Share

  20. LI SM, Zhu FC
    The era of SARS-CoV-2 variants calls for an urgent strategy for COVID-19 vaccination in children.
    Lancet Infect Dis. 2024 Mar 19:S1473-3099(24)00157.
    >> Share


  21. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet Infect Dis. 2024 Mar 19:S1473-3099(24)00007.
    >> Share

  22. ZHANG R, Hung IF
    Bivalent (Omicron BA.5/ancestral) recombinant spike protein vaccine: a promising booster.
    Lancet Infect Dis. 2024 Mar 6:S1473-3099(24)00156.
    >> Share

  23. BENNETT C, Woo W, Bloch M, Cheung K, et al
    Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
    Lancet Infect Dis. 2024 Mar 6:S1473-3099(24)00077.
    >> Share

  24. BILSEN MP, Conroy SP, Schneeberger C, Platteel TN, et al
    A reference standard for urinary tract infection research: a multidisciplinary Delphi consensus study.
    Lancet Infect Dis. 2024 Mar 5:S1473-3099(23)00778.
    >> Share

  25. KOUTSAKOS M, Rockman S, Krammer F
    Is eradication of influenza B viruses possible?
    Lancet Infect Dis. 2024 Mar 4:S1473-3099(24)00132.
    >> Share

    February 2024
  26. POUKKA E, Auranen K, Baum U
    Non-COVID-19 hospitalisation as a negative control outcome in COVID-19 vaccine effectiveness studies.
    Lancet Infect Dis. 2024 Feb 22:S1473-3099(24)00106.
    >> Share

  27. HANSEN CH, Moustsen-Helms IR, Rasmussen M, Soborg B, et al
    Non-COVID-19 hospitalisation as a negative control outcome in COVID-19 vaccine effectiveness studies - Authors' reply.
    Lancet Infect Dis. 2024 Feb 22:S1473-3099(24)00107.
    >> Share

  28. PLEY C, Kampmann B
    Access to respiratory syncytial virus preventive tools for neonates and infants in Europe.
    Lancet Infect Dis. 2024 Feb 19:S1473-3099(24)00084.
    >> Share

  29. FAFI I, Assad Z, Lenglart L, Valtuille Z, et al
    Evolution of respiratory syncytial virus burden in young children following the COVID-19 pandemic: influence of concomitant changes in testing practices.
    Lancet Infect Dis. 2024 Feb 15:S1473-3099(24)00081.
    >> Share

  30. LI Y
    Evolution of respiratory syncytial virus burden in young children following the COVID-19 pandemic: influence of concomitant changes in testing practices - Author's reply.
    Lancet Infect Dis. 2024 Feb 15:S1473-3099(24)00082.
    >> Share

  31. MACHKOVECH HM, Hahn AM, Garonzik Wang J, Grubaugh ND, et al
    Persistent SARS-CoV-2 infection: significance and implications.
    Lancet Infect Dis. 2024 Feb 7:S1473-3099(23)00815.
    >> Share

  32. MARKING U, Bladh O, Aguilera K, Yang Y, et al
    Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden.
    Lancet Infect Dis. 2024;24:e80-e81.
    >> Share

  33. ODA Y, Kumagai Y, Kanai M, Iwama Y, et al
    Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2.
    Lancet Infect Dis. 2024 Feb 1:S1473-3099(24)00060.
    >> Share

  34. BERTRAN M, D'Aeth JC, Abdullahi F, Eletu S, et al
    Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study.
    Lancet Infect Dis. 2024 Feb 1:S1473-3099(23)00706.
    >> Share

    January 2024
  35. DENNING DW
    Global incidence and mortality of severe fungal disease.
    Lancet Infect Dis. 2024 Jan 12:S1473-3099(23)00692.
    >> Share

  36. COSSMANN A, Hoffmann M, Stankov MV, Lurken K, et al
    Immune responses following BNT162b2 XBB.1.5 vaccination in patients on haemodialysis in Germany.
    Lancet Infect Dis. 2024 Jan 8:S1473-3099(23)00783.
    >> Share

  37. KOSUGI Y, Kaku Y, Hinay AA Jr, Guo Z, et al
    Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals.
    Lancet Infect Dis. 2024 Jan 8:S1473-3099(23)00784.
    >> Share

  38. HANSEN CH, Moustsen-Helms IR, Rasmussen M, Soborg B, et al
    Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study.
    Lancet Infect Dis. 2024 Jan 5:S1473-3099(23)00746.
    >> Share

  39. KAKU Y, Okumura K, Padilla-Blanco M, Kosugi Y, et al
    Virological characteristics of the SARS-CoV-2 JN.1 variant.
    Lancet Infect Dis. 2024 Jan 3:S1473-3099(23)00813.
    >> Share

    December 2023
  40. CONG B, Koc U, Bandeira T, Bassat Q, et al
    Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis.
    Lancet Infect Dis. 2023 Dec 20:S1473-3099(23)00630.
    >> Share

  41. ODA Y, Kumagai Y, Kanai M, Iwama Y, et al
    Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Lancet Infect Dis. 2023 Dec 20:S1473-3099(23)00650.
    >> Share

  42. HERFST S, de Vries RD
    Self-amplifying RNA vaccines against antigenically distinct SARS-CoV-2 variants.
    Lancet Infect Dis. 2023 Dec 20:S1473-3099(23)00734.
    >> Share

  43. MONTGOMERY MP, Morris SE, Rolfes MA, Kittikraisak W, et al
    The role of asymptomatic infections in influenza transmission: what do we really know.
    Lancet Infect Dis. 2023 Dec 18:S1473-3099(23)00619.
    >> Share

  44. YANG S, Yu Y, Xu Y, Jian F, et al
    Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure.
    Lancet Infect Dis. 2023 Dec 15:S1473-3099(23)00744.
    >> Share

  45. GANDHI M
    Post-viral sequelae of COVID-19 and influenza.
    Lancet Infect Dis. 2023 Dec 14:S1473-3099(23)00762.
    >> Share

  46. XIE Y, Choi T, Al-Aly Z
    Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study.
    Lancet Infect Dis. 2023 Dec 14:S1473-3099(23)00684.
    >> Share

  47. RAMAN B, Ramasamy MN
    Synbiotics in post-acute COVID-19 syndrome-a potential new treatment framework?
    Lancet Infect Dis. 2023 Dec 7:S1473-3099(23)00735.
    >> Share

  48. LAU RI, Su Q, Lau ISF, Ching JYL, et al
    A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial.
    Lancet Infect Dis. 2023 Dec 7:S1473-3099(23)00685.
    >> Share

  49. ZUO F, Cao Y, Sun R, Yisimayi A, et al
    Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86.
    Lancet Infect Dis. 2023 Dec 7:S1473-3099(23)00732.
    >> Share

  50. CARR EJ, Dowgier G, Greenwood D, Herman LS, et al
    SARS-CoV-2 mucosal neutralising immunity after vaccination.
    Lancet Infect Dis. 2023 Dec 6:S1473-3099(23)00705.
    >> Share

  51. BURKI T
    UK Covid-19 Inquiry.
    Lancet Infect Dis. 2023;23:e516-e517.
    >> Share

  52. BAGCCHI S
    Boost for COVID-19 testing in the USA.
    Lancet Infect Dis. 2023;23:e514.
    >> Share

    November 2023
  53. DE LUSIGNAN S, Hobbs FR, Sheikh A
    Lessons from the English primary care sentinel network's response to the COVID-19 pandemic.
    Lancet Infect Dis. 2023 Nov 28:S1473-3099(23)00736.
    >> Share

  54. GOTTLIEB RL, Paredes R
    Oral and intravenous 1'-cyano-substituted adenosine-like antivirals for early COVID-19.
    Lancet Infect Dis. 2023 Nov 22:S1473-3099(23)00633.
    >> Share

  55. FAN X, Dai X, Ling Y, Wu L, et al
    Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study.
    Lancet Infect Dis. 2023 Nov 22:S1473-3099(23)00577.
    >> Share

  56. STANKOV MV, Hoffmann M, Gutierrez Jauregui R, Cossmann A, et al
    Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination.
    Lancet Infect Dis. 2023 Nov 20:S1473-3099(23)00690.
    >> Share

  57. LASSAUNIERE R, Polacek C, Utko M, Sorensen KM, et al
    Virus isolation and neutralisation of SARS-CoV-2 variants BA.2.86 and EG.5.1.
    Lancet Infect Dis. 2023 Nov 7:S1473-3099(23)00682.
    >> Share

  58. JESUDASON T
    New licensing agreements for COVID-19.
    Lancet Infect Dis. 2023;23:e471.
    >> Share

    October 2023
  59. OLBRICH L, Verghese VP, Franckling-Smith Z, Sabi I, et al
    Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-income countries.
    Lancet Infect Dis. 2023 Oct 30:S1473-3099(23)00491.
    >> Share

  60. SIMPSON CR, Robertson C, McMenamin J, Ritchie LD, et al
    Developing the EAVE III platform for future health crises.
    Lancet Infect Dis. 2023 Oct 12:S1473-3099(23)00626.
    >> Share

  61. GROBUSCH MP, Ruiz Del Portal Luyten C, Visser BJ, de Jong HK, et al
    Overcoming publication and dissemination bias in infectious diseases clinical trials.
    Lancet Infect Dis. 2023 Oct 11:S1473-3099(23)00455.
    >> Share

  62. WANNIGAMA DL, Amarasiri M, Phattharapornjaroen P, Hurst C, et al
    Tracing the new SARS-CoV-2 variant BA.2.86 in the community through wastewater surveillance in Bangkok, Thailand.
    Lancet Infect Dis. 2023 Oct 6:S1473-3099(23)00620.
    >> Share

  63. FAUST JS
    The therapeutic validation of long COVID.
    Lancet Infect Dis. 2023;23:1096-1097.
    >> Share

    September 2023
  64. BRAMANTE C
    The power and pressure placed on clinicians and guideline panels.
    Lancet Infect Dis. 2023 Sep 28:S1473-3099(23)00557.
    >> Share

  65. SCHILLING WHK, Jittamala P, Watson JA, Boyd S, et al
    Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
    Lancet Infect Dis. 2023 Sep 28:S1473-3099(23)00493.
    >> Share

  66. ONYWERA H, Ondoa P, Nfii F, Ogwell A, et al
    Boosting pathogen genomics and bioinformatics workforce in Africa.
    Lancet Infect Dis. 2023 Sep 28:S1473-3099(23)00394.
    >> Share

  67. SHEWARD DJ, Yang Y, Westerberg M, Oling S, et al
    Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses.
    Lancet Infect Dis. 2023 Sep 27:S1473-3099(23)00588.
    >> Share

  68. YANG S, Yu Y, Jian F, Song W, et al
    Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86.
    Lancet Infect Dis. 2023 Sep 19:S1473-3099(23)00573.
    >> Share

  69. URIU K, Ito J, Kosugi Y, Tanaka YL, et al
    Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant.
    Lancet Infect Dis. 2023 Sep 18:S1473-3099(23)00575.
    >> Share

  70. BLOM K, Fjallstrom P, Molnar C, Aberg M, et al
    SARS-CoV-2-related mortality decrease in nursing home residents given multiple COVID-19 boosters.
    Lancet Infect Dis. 2023 Sep 13:S1473-3099(23)00548.
    >> Share

  71. ZHANG L, Kempf A, Nehlmeier I, Cossmann A, et al
    Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3.
    Lancet Infect Dis. 2023 Sep 13:S1473-3099(23)00547.
    >> Share

  72. KAKU Y, Kosugi Y, Uriu K, Ito J, et al
    Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5.
    Lancet Infect Dis. 2023 Sep 11:S1473-3099(23)00553.
    >> Share

  73. WANG Q, Guo Y, Zhang RM, Ho J, et al
    Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6.
    Lancet Infect Dis. 2023 Sep 11:S1473-3099(23)00555.
    >> Share

    August 2023
  74. MARANDA B, Labbe SM, Lurquin M, Brabant P, et al
    Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial.
    Lancet Infect Dis. 2023 Aug 21:S1473-3099(23)00393.
    >> Share

  75. WANG Y, Cao B
    The insights from SARS-CoV-2 antibody treatment for future emerging infectious diseases.
    Lancet Infect Dis. 2023 Aug 21:S1473-3099(23)00454.
    >> Share

  76. ABO YN, Jamrozik E, McCarthy JS, Roestenberg M, et al
    Strategic and scientific contributions of human challenge trials for vaccine development: facts versus fantasy.
    Lancet Infect Dis. 2023 Aug 10:S1473-3099(23)00294.
    >> Share

  77. GRANT R, Benamouzig D, Catton H, Cheng VC, et al
    COVID-19 pandemic: a catalyst for accelerating global action on patient safety.
    Lancet Infect Dis. 2023 Aug 9:S1473-3099(23)00485.
    >> Share

  78. TAN CY, Chiew CJ, Pang D, Lee VJ, et al
    Effectiveness of bivalent mRNA vaccines against medically attended symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive and previously infected individuals: a retrospective cohort study.
    Lancet Infect Dis. 2023 Aug 2:S1473-3099(23)00373.
    >> Share

  79. THE LANCET INFECTIOUS DISEASES
    Where are the long COVID trials?
    Lancet Infect Dis. 2023;23:879.
    >> Share

    July 2023
  80. MADHI SA, Feikin DR
    Are bivalent vaccines better than ancestral-virus monovalent vaccines in protecting against severe omicron COVID-19?
    Lancet Infect Dis. 2023 Jul 18:S1473-3099(23)00425.
    >> Share

  81. MATEO-URDIALES A, Sacco C, Fotakis EA, Del Manso M, et al
    Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study.
    Lancet Infect Dis. 2023 Jul 18:S1473-3099(23)00374.
    >> Share

  82. COHN H, Bloom N, Cai GY, Clark JJ, et al
    Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational study.
    Lancet Infect Dis. 2023 Jul 17:S1473-3099(23)00352.
    >> Share

  83. CERQUEIRA-SILVA T, Boaventura VS, Barral-Netto M
    Effectiveness of monovalent and bivalent COVID-19 vaccines.
    Lancet Infect Dis. 2023 Jul 12:S1473-3099(23)00379.
    >> Share

  84. KIRSEBOM FCM, Andrews N, Stowe J, Ramsay M, et al
    Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study.
    Lancet Infect Dis. 2023 Jul 12:S1473-3099(23)00365.
    >> Share

  85. SCHAEFER GO, Atuire CA, Kaur S, Parker M, et al
    The importance of getting the ethics right in a pandemic treaty.
    Lancet Infect Dis. 2023 Jul 5:S1473-3099(23)00364.
    >> Share

  86. AL-ALY Z
    Prevention of long COVID: progress and challenges.
    Lancet Infect Dis. 2023;23:776-777.
    >> Share

  87. CARR EJ, Wu MY, Gahir J, Harvey R, et al
    Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection.
    Lancet Infect Dis. 2023;23:781-784.
    >> Share

    June 2023
  88. NAKAKUBO S, Kishida N, Okuda K, Kamada K, et al
    Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study.
    Lancet Infect Dis. 2023 Jun 30:S1473-3099(23)00271.
    >> Share

  89. TSUZUKI S
    The future of COVID-19 surveillance in Japan.
    Lancet Infect Dis. 2023 Jun 30:S1473-3099(23)00292.
    >> Share

  90. CRODA J
    Exploring the potential benefits of mucosal COVID-19 vaccines: opportunities and challenges.
    Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00363.
    >> Share

  91. LI JX, Hou LH, Gou JB, Yin ZD, et al
    Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial.
    Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00350.
    >> Share

  92. SOLERA JT, Ierullo M, Arbol BG, Mavandadnejad F, et al
    Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients.
    Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00357.
    >> Share

  93. YAMIN D, Yechezkel M, Arbel R, Beckenstein T, et al
    Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study.
    Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00207.
    >> Share

  94. MADHI SA, Izu A
    Safety of COVID-19 booster dose: is the juice worth the squeeze?
    Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00296.
    >> Share

  95. LEE IT, Cosgrove CA, Moore P, Bethune C, et al
    Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
    Lancet Infect Dis. 2023 Jun 19:S1473-3099(23)00295.
    >> Share

  96. SHANG L, Cao B
    Adapted vaccine strategy: facing the persistent challenges of COVID-19.
    Lancet Infect Dis. 2023 Jun 19:S1473-3099(23)00370.
    >> Share

  97. LIN DY, Xu Y, Gu Y, Zeng D, et al
    Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study.
    Lancet Infect Dis. 2023 Jun 16:S1473-3099(23)00272.
    >> Share

  98. BRAMANTE CT, Buse JB, Liebovitz DM, Nicklas JM, et al
    Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.
    Lancet Infect Dis. 2023 Jun 8:S1473-3099(23)00299.
    >> Share

  99. WALIA K, Mendelson M, Kang G, Venkatasubramanian R, et al
    How can lessons from the COVID-19 pandemic enhance antimicrobial resistance surveillance and stewardship?
    Lancet Infect Dis. 2023 Jun 5:S1473-3099(23)00124.
    >> Share

  100. ALAKIJA A
    Leveraging lessons from the COVID-19 pandemic to strengthen low-income and middle-income country preparedness for future global health threats.
    Lancet Infect Dis. 2023 Jun 5:S1473-3099(23)00279.
    >> Share

  101. KANA BD, Arbuthnot P, Botwe BK, Choonara YE, et al
    Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa.
    Lancet Infect Dis. 2023 Jun 5:S1473-3099(22)00878.
    >> Share

    May 2023
  102. ZHANG R, Hung IF
    CS-2034 mRNA vaccine: a new option for COVID-19 infection?
    Lancet Infect Dis. 2023 May 19:S1473-3099(23)00277.
    >> Share

  103. WU JD, Li JX, Liu J, Wang HM, et al
    Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged >/=18 years: a randomised, double-blind, phase 2b trial.
    Lancet Infect Dis. 2023 May 19:S1473-3099(23)00199.
    >> Share

  104. BHATIA S, Imai N, Watson OJ, Abbood A, et al
    Lessons from COVID-19 for rescalable data collection.
    Lancet Infect Dis. 2023 May 4:S1473-3099(23)00121.
    >> Share

  105. LEE NR, King A, Vigil D, Mullaney D, et al
    Infectious diseases in Indigenous populations in North America: learning from the past to create a more equitable future.
    Lancet Infect Dis. 2023 May 3:S1473-3099(23)00190.
    >> Share

  106. YAMASOBA D, Uriu K, Plianchaisuk A, Kosugi Y, et al
    Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant.
    Lancet Infect Dis. 2023 May 3:S1473-3099(23)00278.
    >> Share

  107. IZU A, Nunes MC, Solomon F, Baillie V, et al
    All-cause and pathogen-specific lower respiratory tract infection hospital admissions in children younger than 5 years during the COVID-19 pandemic (2020-22) compared with the pre-pandemic period (2015-19) in South Africa: an observational study.
    Lancet Infect Dis. 2023 May 1:S1473-3099(23)00200.
    >> Share

  108. LEVY C, Cohen R
    Infectious diseases in the COVID-19 era: gaps between countries.
    Lancet Infect Dis. 2023 May 1:S1473-3099(23)00198.
    >> Share

    April 2023
  109. JUAN-GINER A, Namulwana ML, Kimathi D, Grantz KH, et al
    Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
    Lancet Infect Dis. 2023 Apr 28:S1473-3099(23)00131.
    >> Share

  110. MONACH PA, Branch-Elliman W
    More data needed on efficacy and safety of monovalent vaccines against SARS-CoV-2 omicron variants.
    Lancet Infect Dis. 2023 Apr 26:S1473-3099(23)00274.
    >> Share

  111. VASIN AV, Stukova MA
    Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2.
    Lancet Infect Dis. 2023 Apr 20:S1473-3099(23)00189.
    >> Share

  112. TAN NH, Geers D, Sablerolles RSG, Rietdijk WJR, et al
    Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
    Lancet Infect Dis. 2023 Apr 20:S1473-3099(23)00140.
    >> Share

  113. STOLIAROFF-PEPIN A, Harder T
    Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations.
    Lancet Infect Dis. 2023 Apr 13:S1473-3099(23)00187.
    >> Share

  114. ARBEL R, Peretz A, Sergienko R, Friger M, et al
    Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study.
    Lancet Infect Dis. 2023 Apr 13:S1473-3099(23)00122.
    >> Share

  115. JENKIN D, Wright D, Folegatti PM, Platt A, et al
    Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial.
    Lancet Infect Dis. 2023 Apr 12:S1473-3099(23)00068.
    >> Share

  116. SOLERA JT, Arbol BG, Ferreira VH, Kurtesi A, et al
    Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab-cilgavimab.
    Lancet Infect Dis. 2023 Apr 5:S1473-3099(23)00208.
    >> Share

  117. IWASAKI A, Putrino D
    Why we need a deeper understanding of the pathophysiology of long COVID.
    Lancet Infect Dis. 2023;23:393-395.
    >> Share

  118. URAKI R, Ito M, Kiso M, Yamayoshi S, et al
    Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate.
    Lancet Infect Dis. 2023;23:402-403.
    >> Share

    March 2023
  119. WANG Q, Bowen A, Tam AR, Valdez R, et al
    SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster.
    Lancet Infect Dis. 2023 Mar 29:S1473-3099(23)00181.
    >> Share

  120. EYRE DW, Futschik M, Tunkel S, Wei J, et al
    Performance of antigen lateral flow devices in the UK during the alpha, delta, and omicron waves of the SARS-CoV-2 pandemic: a diagnostic and observational study.
    Lancet Infect Dis. 2023 Mar 28:S1473-3099(23)00129.
    >> Share

  121. PRESTEDGE J, Williamson DA
    The performance of rapid antigen tests against SARS-CoV-2 variants.
    Lancet Infect Dis. 2023 Mar 28:S1473-3099(23)00186.
    >> Share

  122. WILKINS D, Langedijk AC, Lebbink RJ, Morehouse C, et al
    Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data.
    Lancet Infect Dis. 2023 Mar 17:S1473-3099(23)00062.
    >> Share

  123. LEWNARD JA, McLaughlin JM, Malden D, Hong V, et al
    Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.
    Lancet Infect Dis. 2023 Mar 15:S1473-3099(23)00118.
    >> Share

  124. TAN CY, Chiew CJ, Pang D, Lee VJ, et al
    Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
    Lancet Infect Dis. 2023 Mar 13:S1473-3099(23)00060.
    >> Share

  125. BOYTON RJ, Altmann DM
    Imprinted hybrid immunity against XBB reinfection.
    Lancet Infect Dis. 2023 Mar 13:S1473-3099(23)00138.
    >> Share

  126. CHEMAITELLY H, Ayoub HH, Tang P, Coyle P, et al
    Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study.
    Lancet Infect Dis. 2023 Mar 10:S1473-3099(23)00058.
    >> Share

  127. URAKI R, Ito M, Kiso M, Yamayoshi S, et al
    Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1.
    Lancet Infect Dis. 2023 Mar 7:S1473-3099(23)00132.
    >> Share

  128. KUIKEN T, Fouchier RAM, Koopmans MPG
    Being ready for the next influenza pandemic?
    Lancet Infect Dis. 2023 Mar 7:S1473-3099(23)00117.
    >> Share

  129. KIRBY T
    Alemka Markotic-from hantavirus to COVID-19.
    Lancet Infect Dis. 2023;23:292.
    >> Share

  130. SOTO-RIFO R
    Durability of AZD1222 and hybrid humoral immunity against omicron BA.1 and BA.4.
    Lancet Infect Dis. 2023;23:262-263.
    >> Share

    February 2023
  131. HUANG J, Zhao S, Chong KC, Zhou Y, et al
    Infection rate in Guangzhou after easing the zero-COVID policy: seroprevalence results to ORF8 antigen.
    Lancet Infect Dis. 2023 Feb 17:S1473-3099(23)00112.
    >> Share

  132. WONG CKH, Lau KTK, Au ICH, Lau EHY, et al
    Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study.
    Lancet Infect Dis. 2023 Feb 13:S1473-3099(22)00873.
    >> Share

  133. PETROSILLO N
    SARS-CoV-2 rebound with and without antivirals.
    Lancet Infect Dis. 2023 Feb 13:S1473-3099(23)00063.
    >> Share

  134. AGGARWAL NR, Molina KC, Beaty LE, Bennett TD, et al
    Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
    Lancet Infect Dis. 2023 Feb 10:S1473-3099(23)00011.
    >> Share

  135. WONG CKH, Lau KTK, Leung GM
    Real-world effectiveness of nirmatrelvir-ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants.
    Lancet Infect Dis. 2023 Feb 10:S1473-3099(23)00056.
    >> Share

  136. YUE C, Song W, Wang L, Jian F, et al
    ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5.
    Lancet Infect Dis. 2023 Feb 3:S1473-3099(23)00010.
    >> Share

  137. CHEMAITELLY H, Ayoub HH, Coyle P, Tang P, et al
    BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents.
    Lancet Infect Dis. 2023 Feb 1:S1473-3099(23)00005.
    >> Share

    January 2023
  138. URIU K, Ito J, Zahradnik J, Fujita S, et al
    Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant.
    Lancet Infect Dis. 2023 Jan 31:S1473-3099(23)00051.
    >> Share

  139. HOEHL S, Ciesek S
    Recalling ancestral SARS-CoV-2 variants: is it an original sin with benefits?
    Lancet Infect Dis. 2023 Jan 30:S1473-3099(23)00007.
    >> Share

  140. HE G, Jones JA, Sun W
    COVID-19 travel policies for people from China and discrimination.
    Lancet Infect Dis. 2023 Jan 30:S1473-3099(23)00052.
    >> Share

  141. GIACOBBE DR, Bassetti M
    Too many antibiotics for patients with COVID-19 despite low bacterial infections.
    Lancet Infect Dis. 2023 Jan 27:S1473-3099(22)00866.
    >> Share

  142. CHEN JZ, Hoang HL, Yaskina M, Kabbani D, et al
    Efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients hospitalised with COVID-19 (COVASP): a pragmatic, cluster-randomised, non-inferiority trial.
    Lancet Infect Dis. 2023 Jan 27:S1473-3099(22)00832.
    >> Share

  143. BOAVENTURA VS, Cerqueira-Silva T, Barral-Netto M
    The benefit of vaccination after previous SARS-CoV-2 infection in the omicron era.
    Lancet Infect Dis. 2023 Jan 18:S1473-3099(22)00880.
    >> Share

  144. BOBROVITZ N, Ware H, Ma X, Li Z, et al
    Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression.
    Lancet Infect Dis. 2023 Jan 18:S1473-3099(22)00801.
    >> Share

  145. FADLYANA E, Setiabudi D, Kartasasmita CB, Putri ND, et al
    Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial
    Lancet Infect Dis. 2023 Jan 11:S1473-3099(22)00800.
    >> Share

  146. MARKING U, Bladh O, Havervall S, Svensson J, et al
    7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection.
    Lancet Infect Dis. 2023 Jan 11:S1473-3099(22)00834.
    >> Share

  147. NILLES EJ, Paulino CT, de St Aubin M, Duke W, et al
    Tracking immune correlates of protection for emerging SARS-CoV-2 variants.
    Lancet Infect Dis. 2023 Jan 11:S1473-3099(23)00001.
    >> Share

  148. BRADY OJ, Hofmann B, Colon-Gonzalez FJ, Gibb R, et al
    Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting.
    Lancet Infect Dis. 2023 Jan 6:S1473-3099(23)00003.
    >> Share

  149. ARORA P, Cossmann A, Schulz SR, Ramos GM, et al
    Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage.
    Lancet Infect Dis. 2023 Jan 5:S1473-3099(22)00831.
    >> Share

  150. MALATO J, Ribeiro RM, Fernandes E, Leite PP, et al
    Stability of hybrid versus vaccine immunity against BA.5 infection over 8 months.
    Lancet Infect Dis. 2023 Jan 5:S1473-3099(22)00833.
    >> Share

    December 2022
  151. NACHEGA JB, Nsanzimana S, Rawat A, Wilson LA, et al
    Advancing detection and response capacities for emerging and re-emerging pathogens in Africa.
    Lancet Infect Dis. 2022 Dec 20:S1473-3099(22)00723.
    >> Share

  152. TSALIK EL, Rouphael NG, Sadikot RT, Rodriguez-Barradas MC, et al
    Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trial.
    Lancet Infect Dis. 2022 Dec 13:S1473-3099(22)00735.
    >> Share

  153. TSANG NNY, So HC, Cowling BJ, Leung GM, et al
    Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Lancet Infect Dis. 2022 Dec 12:S1473-3099(22)00732.
    >> Share

  154. BRYANT OK, Man KKC, Jani YH, Wong ICK, et al
    Antibiotic prescribing in general practice during COVID-19 and beyond.
    Lancet Infect Dis. 2022 Dec 7:S1473-3099(22)00814.
    >> Share

  155. HOFFMANN M, Behrens GMN, Arora P, Kempf A, et al
    Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation.
    Lancet Infect Dis. 2022 Dec 5:S1473-3099(22)00792.
    >> Share

  156. FLORENTINO PTV, Alves FJO, Cerqueira-Silva T, de Araujo Oliveira V, et al
    Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil.
    Lancet Infect Dis. 2022;22:1669-1670.
    >> Share

  157. DEN HARTOG G, van Kasteren PB, Schepp RM, Teirlinck AC, et al
    Decline of RSV-specific antibodies during the COVID-19 pandemic.
    Lancet Infect Dis. 2022 Dec 1:S1473-3099(22)00763.
    >> Share

    November 2022
  158. POWELL AA, Kirsebom F, Stowe J, Ramsay ME, et al
    Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-neg
    Lancet Infect Dis. 2022 Nov 24:S1473-3099(22)00729.
    >> Share

  159. IRVING SA, Buchan SA
    Considerations of hybrid immunity and the future of adolescent COVID-19 vaccination.
    Lancet Infect Dis. 2022 Nov 24:S1473-3099(22)00759.
    >> Share

  160. ARORA P, Kempf A, Nehlmeier I, Schulz SR, et al
    Omicron sublineage BQ.1.1 resistance to monoclonal antibodies.
    Lancet Infect Dis. 2022 Nov 18:S1473-3099(22)00733.
    >> Share

  161. LINDHOLM DA, Kalil AC
    Deja vu all over again? Monkeypox and the urgent need for randomised controlled trials.
    Lancet Infect Dis. 2022 Nov 15. pii: S1473-3099(22)00722.
    >> Share

  162. KENNEDY RB
    Monkeypox infection creates immune signatures of disease progression.
    Lancet Infect Dis. 2022 Nov 7. pii: S1473-3099(22)00691.
    >> Share

  163. NICHOLS RM, Deveau C, Upadhyaya H
    Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic.
    Lancet Infect Dis. 2022;22:1531.
    >> Share

    October 2022
  164. WANG Q, Li Z, Ho J, Guo Y, et al
    Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation.
    Lancet Infect Dis. 2022 Oct 31. pii: S1473-3099(22)00694.
    >> Share

  165. ARORA P, Zhang L, Nehlmeier I, Kempf A, et al
    The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages.
    Lancet Infect Dis. 2022 Oct 31. pii: S1473-3099(22)00693.
    >> Share

  166. PRENDECKI M, Willicombe M
    SARS-CoV-2 vaccine strategies in kidney transplant recipients.
    Lancet Infect Dis. 2022 Oct 27. pii: S1473-3099(22)00666.
    >> Share

  167. KHO MML, Messchendorp AL, Frolke SC, Imhof C, et al
    Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial.
    Lancet Infect Dis. 2022 Oct 27. pii: S1473-3099(22)00650.
    >> Share

  168. DORON S, Gandhi M
    New boosters are here! Who should receive them and when?
    Lancet Infect Dis. 2022 Oct 27. pii: S1473-3099(22)00688.
    >> Share

  169. TARTOF SY, Slezak JM, Puzniak L, Hong V, et al
    BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5.
    Lancet Infect Dis. 2022 Oct 25. pii: S1473-3099(22)00692.
    >> Share

  170. MADHI SA, Kwatra G, Richardson SI, Koen AL, et al
    Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
    Lancet Infect Dis. 2022 Oct 20. pii: S1473-3099(22)00596.
    >> Share

  171. STANDING JF, Agyeman AA
    Learning and confirming in publicly funded antiviral trials.
    Lancet Infect Dis. 2022 Oct 19. pii: S1473-3099(22)00665.
    >> Share

  172. KHOO SH, FitzGerald R, Saunders G, Middleton C, et al
    Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
    Lancet Infect Dis. 2022 Oct 19. pii: S1473-3099(22)00644.
    >> Share

  173. HANSEN CH, Friis NU, Bager P, Stegger M, et al
    Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark.
    Lancet Infect Dis. 2022 Oct 18. pii: S1473-3099(22)00595.
    >> Share

  174. ANGELO KM, Smith T, Camprubi-Ferrer D, Balerdi-Sarasola L, et al
    Epidemiological and clinical characteristics of patients with monkeypox in the GeoSentinel Network: a cross-sectional study.
    Lancet Infect Dis. 2022 Oct 7. pii: S1473-3099(22)00651.
    >> Share

  175. LLEWELYN MJ, Budgell EP, Laskawiec-Szkonter M, Cross ELA, et al
    Antibiotic review kit for hospitals (ARK-Hospital): a stepped-wedge cluster-randomised controlled trial.
    Lancet Infect Dis. 2022 Oct 4. pii: S1473-3099(22)00508.
    >> Share

  176. RANSCOMBE P
    Dr Hammond's COVID-19 inquiry.
    Lancet Infect Dis. 2022;22:1433.
    >> Share

    September 2022
  177. CHIEW CJ, Premikha M, Chong CY, Wei WE, et al
    Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study.
    Lancet Infect Dis. 2022 Sep 28. pii: S1473-3099(22)00573.
    >> Share

  178. JIAN F, Yu Y, Song W, Yisimayi A, et al
    Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants.
    Lancet Infect Dis. 2022 Sep 27. pii: S1473-3099(22)00642.
    >> Share

  179. MAITEKI-SEBUGUZI C, Gonahasa S, Kamya MR, Katureebe A, et al
    Effect of long-lasting insecticidal nets with and without piperonyl butoxide on malaria indicators in Uganda (LLINEUP): final results of a cluster-randomised trial embedded in a national distribution campaign.
    Lancet Infect Dis. 2022 Sep 26. pii: S1473-3099(22)00469.
    >> Share

  180. BANDYOPADHYAY AS, Zipursky S
    A novel tool to eradicate an ancient scourge: the novel oral polio vaccine type 2 story.
    Lancet Infect Dis. 2022 Sep 23. pii: S1473-3099(22)00582.
    >> Share

  181. CARAZO S, Skowronski DM, Brisson M, Barkati S, et al
    Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study.
    Lancet Infect Dis. 2022 Sep 21. pii: S1473-3099(22)00578.
    >> Share

  182. HUI DS
    Hybrid immunity and strategies for COVID-19 vaccination.
    Lancet Infect Dis. 2022 Sep 21. pii: S1473-3099(22)00640.
    >> Share

  183. ARORA P, Nehlmeier I, Kempf A, Cossmann A, et al
    Lung cell entry, cell-cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75.
    Lancet Infect Dis. 2022 Sep 15. pii: S1473-3099(22)00591.
    >> Share

  184. POLAND GA, Kennedy RB, Tosh PK
    Prevention of monkeypox with vaccines: a rapid review.
    Lancet Infect Dis. 2022 Sep 15. pii: S1473-3099(22)00574.
    >> Share

  185. HARDT K, Vandebosch A, Sadoff J, Le Gars M, et al
    Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Infect Dis. 2022 Sep 13. pii: S1473-3099(22)00506.
    >> Share

  186. AMIR O, Goldberg Y, Mandel M, Bar-On YM, et al
    Initial protection against SARS-CoV-2 omicron lineage infection in children and adolescents by BNT162b2 in Israel: an observational study.
    Lancet Infect Dis. 2022 Sep 9. pii: S1473-3099(22)00527.
    >> Share

  187. IRVING SA, Klein NP
    COVID-19 vaccination protects children and adolescents.
    Lancet Infect Dis. 2022 Sep 9. pii: S1473-3099(22)00575.
    >> Share

  188. GRUELL H, Vanshylla K, Tober-Lau P, Hillus D, et al
    Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage.
    Lancet Infect Dis. 2022 Sep 6. pii: S1473-3099(22)00580.
    >> Share

  189. LAZARUS R, Querton B, Corbic Ramljak I, Dewasthaly S, et al
    Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.
    Lancet Infect Dis. 2022 Sep 5. pii: S1473-3099(22)00502.
    >> Share

  190. GEURTSVANKESSEL CH, de Vries RD
    Evaluating novel COVID-19 vaccines in the current chapter of the pandemic.
    Lancet Infect Dis. 2022 Sep 5. pii: S1473-3099(22)00517.
    >> Share

  191. BARDSLEY M, Morbey RA, Hughes HE, Beck CR, et al
    Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational study.
    Lancet Infect Dis. 2022 Sep 2. pii: S1473-3099(22)00525.
    >> Share

  192. BILLARD MN, Bont LJ
    Quantifying the RSV immunity debt following COVID-19: a public health matter.
    Lancet Infect Dis. 2022 Sep 2. pii: S1473-3099(22)00544.
    >> Share

    August 2022
  193. WELLS CR, Galvani AP
    Tackling the politicisation of COVID-19 data reporting through open access data sharing.
    Lancet Infect Dis. 2022 Aug 31. pii: S1473-3099(22)00505.
    >> Share

  194. DONG E, Ratcliff J, Goyea TD, Katz A, et al
    The Johns Hopkins University Center for Systems Science and Engineering COVID-19 Dashboard: data collection process, challenges faced, and lessons learned.
    Lancet Infect Dis. 2022 Aug 31. pii: S1473-3099(22)00434.
    >> Share

  195. AABY P, Netea MG, Benn CS
    Beneficial non-specific effects of live vaccines against COVID-19 and other unrelated infections.
    Lancet Infect Dis. 2022 Aug 26. pii: S1473-3099(22)00498.
    >> Share

  196. GAVRIILAKI E, Kokoris S
    COVID-19 sequelae: can long-term effects be predicted?
    Lancet Infect Dis. 2022 Aug 25. pii: S1473-3099(22)00529.
    >> Share

  197. PERICO N, Cortinovis M, Suter F, Remuzzi G, et al
    Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents.
    Lancet Infect Dis. 2022 Aug 25. pii: S1473-3099(22)00433.
    >> Share

  198. DEUEL JW, Lauria E, Lovey T, Zweifel S, et al
    Persistence, prevalence, and polymorphism of sequelae after COVID-19 in unvaccinated, young adults of the Swiss Armed Forces: a longitudinal, cohort study (LoCoMo).
    Lancet Infect Dis. 2022 Aug 25. pii: S1473-3099(22)00449.
    >> Share

  199. ZAREBSKA-MICHALUK D, Flisiak R
    Early oral antiviral use in patients hospitalised with COVID-19.
    Lancet Infect Dis. 2022 Aug 24. pii: S1473-3099(22)00522.
    >> Share

  200. WONG CKH, Au ICH, Lau KTK, Lau EHY, et al
    Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
    Lancet Infect Dis. 2022 Aug 24. pii: S1473-3099(22)00507.
    >> Share

  201. HALFORD F, Nash S, Tessier E, Kall M, et al
    Variation in reported SARS-CoV-2 cases after testing policy changes.
    Lancet Infect Dis. 2022 Aug 23. pii: S1473-3099(22)00572.
    >> Share

  202. FAUST JS, Renton B, Chen AJ, Du C, et al
    Uncoupling of all-cause excess mortality from COVID-19 cases in a highly vaccinated state.
    Lancet Infect Dis. 2022 Aug 22. pii: S1473-3099(22)00547.
    >> Share

  203. FRANCO-PAREDES C, Rodriguez-Morales AJ, Henao-Martinez AF, Carrasco P, et al
    The growing threat of wild poliovirus 1 and vaccine-derived cases in the COVID-19 era.
    Lancet Infect Dis. 2022 Aug 16. pii: S1473-3099(22)00548.
    >> Share

  204. ELLINGTON S, Olson CK
    Safety of mRNA COVID-19 vaccines during pregnancy.
    Lancet Infect Dis. 2022 Aug 11. pii: S1473-3099(22)00443.
    >> Share

  205. SADARANGANI M, Soe P, Shulha HP, Valiquette L, et al
    Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) network cohort study.
    Lancet Infect Dis. 2022 Aug 11. pii: S1473-3099(22)00426.
    >> Share

  206. MALLORY RM, Formica N, Pfeiffer S, Wilkinson B, et al
    Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
    Lancet Infect Dis. 2022 Aug 10. pii: S1473-3099(22)00420.
    >> Share

  207. RYCKMAN T, Robsky K, Cilloni L, Zawedde-Muyanja S, et al
    Ending tuberculosis in a post-COVID-19 world: a person-centred, equity-oriented approach.
    Lancet Infect Dis. 2022 Aug 10. pii: S1473-3099(22)00500.
    >> Share

  208. FLORENTINO PTV, Millington T, Cerqueira-Silva T, Robertson C, et al
    Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study.
    Lancet Infect Dis. 2022 Aug 8. pii: S1473-3099(22)00451.
    >> Share

  209. MARTIN GE, Taiaroa G, Taouk ML, Savic I, et al
    Maintaining genomic surveillance using whole-genome sequencing of SARS-CoV-2 from rapid antigen test devices.
    Lancet Infect Dis. 2022 Aug 4. pii: S1473-3099(22)00512.
    >> Share

    July 2022
  210. MCMENAMIN ME, Nealon J, Lin Y, Wong JY, et al
    Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study.
    Lancet Infect Dis. 2022 Jul 15. pii: S1473-3099(22)00345.
    >> Share

  211. SUN F, Lin Y, Wang X, Gao Y, et al
    Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection.
    Lancet Infect Dis. 2022 Jul 14. pii: S1473-3099(22)00430.
    >> Share

  212. HERMAN GA, O'Brien MP, Forleo-Neto E, Sarkar N, et al
    Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.
    Lancet Infect Dis. 2022 Jul 5. pii: S1473-3099(22)00416.
    >> Share

  213. FOCOSI D, McConnell S, Casadevall A, Cappello E, et al
    Monoclonal antibody therapies against SARS-CoV-2.
    Lancet Infect Dis. 2022 Jul 5. pii: S1473-3099(22)00311.
    >> Share

  214. GOTTLIEB RL, Razonable RR
    Stewardship of COVID-19 volunteers by nested trial design.
    Lancet Infect Dis. 2022 Jul 5. pii: S1473-3099(22)00429.
    >> Share

  215. BALAKRISHNAN VS
    2 years of the Access to COVID-19 Tools-Accelerator.
    Lancet Infect Dis. 2022;22:948.
    >> Share

  216. SPANER C, Goubran M, Setiadi A, Chen LYC, et al
    COVID-19, haemophagocytic lymphohistiocytosis, and infection-induced cytokine storm syndromes.
    Lancet Infect Dis. 2022;22:937-938.
    >> Share

    June 2022
  217. ARORA P, Kempf A, Nehlmeier I, Schulz SR, et al
    Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5.
    Lancet Infect Dis. 2022 Jun 28. pii: S1473-3099(22)00422.
    >> Share

  218. LEACH AJ, Wilson N, Arrowsmith B, Beissbarth J, et al
    Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled tr
    Lancet Infect Dis. 2022 Jun 27. pii: S1473-3099(22)00272.
    >> Share

  219. MARIATULQABTIAH AR, Buttigieg KR
    COVID-19 vaccinations for children.
    Lancet Infect Dis. 2022 Jun 24. pii: S1473-3099(22)00414.
    >> Share

  220. WELLS CR, Galvani AP
    The global impact of disproportionate vaccination coverage on COVID-19 mortality.
    Lancet Infect Dis. 2022 Jun 23. pii: S1473-3099(22)00417.
    >> Share

  221. WATSON OJ, Barnsley G, Toor J, Hogan AB, et al
    Global impact of the first year of COVID-19 vaccination: a mathematical modelling study.
    Lancet Infect Dis. 2022 Jun 23. pii: S1473-3099(22)00320.
    >> Share

  222. HIGDON MM, Baidya A, Walter KK, Patel MK, et al
    Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant.
    Lancet Infect Dis. 2022 Jun 22. pii: S1473-3099(22)00409.
    >> Share

  223. VADREVU KM, Reddy S, Jogdand H, Ganneru B, et al
    Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study.
    Lancet Infect Dis. 2022 Jun 16. pii: S1473-3099(22)00307.
    >> Share

  224. BLOM K, Marking U, Havervall S, Norin NG, et al
    Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection.
    Lancet Infect Dis. 2022 Jun 9. pii: S1473-3099(22)00362.
    >> Share

  225. YAMASOBA D, Kosugi Y, Kimura I, Fujita S, et al
    Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies.
    Lancet Infect Dis. 2022 Jun 8. pii: S1473-3099(22)00365.
    >> Share

  226. USHER AD
    FIND documents dramatic reduction in COVID-19 testing.
    Lancet Infect Dis. 2022 Jun 2. pii: S1473-3099(22)00376.
    >> Share

  227. MONGE S, Rojas-Benedicto A, Olmedo C, Mazagatos C, et al
    Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study.
    Lancet Infect Dis. 2022 Jun 2. pii: S1473-3099(22)00292.
    >> Share

  228. ADER F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, et al
    Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19.
    Lancet Infect Dis. 2022;22:764-765.
    >> Share

  229. BRADY OJ, Tian H
    Additional considerations for assessing COVID-19 impact on dengue transmission - Authors' reply.
    Lancet Infect Dis. 2022;22:763.
    >> Share

  230. YEK C, Pacheco AR, Lon C, Leang R, et al
    Additional considerations for assessing COVID-19 impact on dengue transmission.
    Lancet Infect Dis. 2022;22:762-763.
    >> Share

    May 2022
  231. TRAEGER MW, Guy R, Asselin J, Patel P, et al
    Real-world trends in incidence of bacterial sexually transmissible infections among gay and bisexual men using HIV pre-exposure prophylaxis (PrEP) in Australia following nationwide PrEP implementation: an analysis of sentinel surveillance data.
    Lancet Infect Dis. 2022 May 25. pii: S1473-3099(22)00175.
    >> Share

  232. KIRSEBOM FCM, Andrews N, Stowe J, Toffa S, et al
    COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England.
    Lancet Infect Dis. 2022 May 24. pii: S1473-3099(22)00309.
    >> Share

  233. BURN E, Duarte-Salles T, Fernandez-Bertolin S, Reyes C, et al
    Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study.
    Lancet Infect Dis. 2022 May 13. pii: S1473-3099(22)00223.
    >> Share

  234. WHITELEY W, Wood A
    Risk of arterial and venous thromboses after COVID-19.
    Lancet Infect Dis. 2022 May 13. pii: S1473-3099(22)00314.
    >> Share

  235. LOUBET P, Launay O
    What a second booster dose of mRNA COVID-19 vaccines tells us.
    Lancet Infect Dis. 2022 May 9. pii: S1473-3099(22)00282.
    >> Share

  236. MUNRO APS, Feng S, Janani L, Cornelius V, et al
    Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomis
    Lancet Infect Dis. 2022 May 9. pii: S1473-3099(22)00271.
    >> Share

  237. ROMERO-OLMEDO AJ, Schulz AR, Hochstatter S, Gupta DD, et al
    Dynamics of humoral and T-cell immunity after three BNT162b2 vaccinations in adults older than 80 years.
    Lancet Infect Dis. 2022;22:588-589.
    >> Share

  238. SANCHEZ L, Oviedo Rouco S, Pifano M, Ojeda DS, et al
    Antibody durability at 1 year after Sputnik V vaccination.
    Lancet Infect Dis. 2022;22:589-590.
    >> Share

    April 2022
  239. ODONE A, Vigezzi GP, Baldanti F
    Implications of COVID-19 vaccine effectiveness waning for public health.
    Lancet Infect Dis. 2022 Apr 22. pii: S1473-3099(22)00233.
    >> Share

  240. ADLHOCH C, Gomes HC
    Sustainability of surveillance systems for SARS-CoV-2.
    Lancet Infect Dis. 2022 Apr 22. pii: S1473-3099(22)00174.
    >> Share

  241. SHEIKH A, Kerr S, Woolhouse M, McMenamin J, et al
    Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design.
    Lancet Infect Dis. 2022 Apr 22. pii: S1473-3099(22)00141.
    >> Share

  242. BAGER P, Wohlfahrt J, Bhatt S, Stegger M, et al
    Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study.
    Lancet Infect Dis. 2022 Apr 22. pii: S1473-3099(22)00154.
    >> Share

  243. SMOLENOV I, Han HH, Li P, Baccarini C, et al
    Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial.
    Lancet Infect Dis. 2022 Apr 18. pii: S1473-3099(22)00144.
    >> Share

  244. LI JX, Zhu FC
    The S-Trimer (SCB-2019) COVID-19 vaccine and reinfection with SARS-CoV-2.
    Lancet Infect Dis. 2022 Apr 18. pii: S1473-3099(22)00162.
    >> Share

  245. LORTHE E, Bellon M, Berthelot J, Michielin G, et al
    A SARS-CoV-2 omicron (B.1.1.529) variant outbreak in a primary school in Geneva, Switzerland.
    Lancet Infect Dis. 2022 Apr 14. pii: S1473-3099(22)00267.
    >> Share

  246. CRAWSHAW AF, Farah Y, Deal A, Rustage K, et al
    Defining the determinants of vaccine uptake and undervaccination in migrant populations in Europe to improve routine and COVID-19 vaccine uptake: a systematic review.
    Lancet Infect Dis. 2022 Apr 13. pii: S1473-3099(22)00066.
    >> Share

  247. ARORA P, Zhang L, Rocha C, Sidarovich A, et al
    Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3.
    Lancet Infect Dis. 2022 Apr 12. pii: S1473-3099(22)00224.
    >> Share

  248. WANG B, Giles L, Andraweera P, McMillan M, et al
    Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study.
    Lancet Infect Dis. 2022 Apr 12. pii: S1473-3099(21)00754.
    >> Share

  249. MENNI C, May A, Polidori L, Louca P, et al
    COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
    Lancet Infect Dis. 2022 Apr 8. pii: S1473-3099(22)00146.
    >> Share

  250. MUTHU V, Agarwal R, Patel A, Kathirvel S, et al
    Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India.
    Lancet Infect Dis. 2022 Apr 4. pii: S1473-3099(22)00124.
    >> Share

  251. KIRBY T
    Kanta Subbarao-confronting influenza and COVID-19.
    Lancet Infect Dis. 2022;22:460.
    >> Share

  252. BURKI T
    Hong Kong's fifth COVID-19 wave-the worst yet.
    Lancet Infect Dis. 2022;22:455-456.
    >> Share

  253. THIRUVENGADAM R, Awasthi A, Bhatnagar S, Garg PK, et al
    Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India - Authors' reply.
    Lancet Infect Dis. 2022;22:447.
    >> Share

  254. CHAKRABARTI S, Chakrabarti SS, Chandan G, Kaur U, et al
    Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India.
    Lancet Infect Dis. 2022;22:446-447.
    >> Share

  255. DYSON L
    Modelling results on the impact of COVID-19 testing in schools.
    Lancet Infect Dis. 2022 Apr 1. pii: S1473-3099(22)00163.
    >> Share

  256. COLOSI E, Bassignana G, Contreras DA, Poirier C, et al
    Screening and vaccination against COVID-19 to minimise school closure: a modelling study.
    Lancet Infect Dis. 2022 Apr 1. pii: S1473-3099(22)00138.
    >> Share

    March 2022
  257. NORDSTROM P, Ballin M, Nordstrom A
    Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden.
    Lancet Infect Dis. 2022 Mar 31. pii: S1473-3099(22)00143.
    >> Share

  258. GARG PK, Thiruvengadam R
    Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world.
    Lancet Infect Dis. 2022 Mar 31. pii: S1473-3099(22)00207.
    >> Share

  259. TAN HX, Juno JA
    Interplay of infection and vaccination in long-term protection from COVID-19.
    Lancet Infect Dis. 2022 Mar 31. pii: S1473-3099(22)00210.
    >> Share

  260. CERQUEIRA-SILVA T, Andrews JR, Boaventura VS, Ranzani OT, et al
    Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
    Lancet Infect Dis. 2022 Mar 31. pii: S1473-3099(22)00140.
    >> Share

  261. DAL-RE R, Becker SL, Bottieau E, Holm S, et al
    Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach.
    Lancet Infect Dis. 2022 Mar 29. pii: S1473-3099(22)00119.
    >> Share

  262. POWELL AA, Kirsebom F, Stowe J, McOwat K, et al
    Effectiveness of BNT162b2 against COVID-19 in adolescents.
    Lancet Infect Dis. 2022 Mar 21. pii: S1473-3099(22)00177.
    >> Share

  263. SHEWARD DJ, Kim C, Ehling RA, Pankow A, et al
    Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.
    Lancet Infect Dis. 2022 Mar 17. pii: S1473-3099(22)00129.
    >> Share

  264. PARKER A, Dawood H
    SARS-CoV-2 transmission: time to rethink public health strategy.
    Lancet Infect Dis. 2022 Mar 14. pii: S1473-3099(22)00137.
    >> Share

  265. COHEN C, Kleynhans J, von Gottberg A, McMorrow ML, et al
    SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21.
    Lancet Infect Dis. 2022 Mar 14. pii: S1473-3099(22)00069.
    >> Share

  266. WELKER J, Pulido JD, Catanzaro AT, Malvestutto CD, et al
    Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet Infect Dis. 2022 Mar 11. pii: S1473-3099(22)00058.
    >> Share

  267. ECKHARDT CM, O'Donnell MR
    CD24Fc: an emerging COVID-19 therapy.
    Lancet Infect Dis. 2022 Mar 11. pii: S1473-3099(22)00125.
    >> Share

  268. PARKER EPK, Desai S, Marti M, O'Brien KL, et al
    Emerging evidence on heterologous COVID-19 vaccine schedules-To mix or not to mix?
    Lancet Infect Dis. 2022 Mar 9. pii: S1473-3099(22)00178.
    >> Share

  269. KRANTZ MS, Phillips EJ
    COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA.
    Lancet Infect Dis. 2022 Mar 7. pii: S1473-3099(22)00123.
    >> Share

  270. ROSENBLUM HG, Gee J, Liu R, Marquez PL, et al
    Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe.
    Lancet Infect Dis. 2022 Mar 7. pii: S1473-3099(22)00054.
    >> Share

  271. DEAN AS, Tosas Auguet O, Glaziou P, Zignol M, et al
    25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward.
    Lancet Infect Dis. 2022 Mar 3. pii: S1473-3099(21)00808.
    >> Share

  272. NTOUMI F, Nachega JB, Aklillu E, Chakaya J, et al
    World Tuberculosis Day 2022: aligning COVID-19 and tuberculosis innovations to save lives and to end tuberculosis.
    Lancet Infect Dis. 2022 Mar 3. pii: S1473-3099(22)00142.
    >> Share

  273. SASMONO RT, Santoso MS
    Movement dynamics: reduced dengue cases during the COVID-19 pandemic.
    Lancet Infect Dis. 2022 Mar 2. pii: S1473-3099(22)00062.
    >> Share

  274. CHEN Y, Li N, Lourenco J, Wang L, et al
    Measuring the effects of COVID-19-related disruption on dengue transmission in southeast Asia and Latin America: a statistical modelling study.
    Lancet Infect Dis. 2022 Mar 2. pii: S1473-3099(22)00025.
    >> Share

  275. KIRBY T
    Wolfgang Preiser-co-discoverer of SARS-CoV-2 variants.
    Lancet Infect Dis. 2022;22:326.
    >> Share

  276. BURKI T
    Education services in crisis due to COVID-19.
    Lancet Infect Dis. 2022;22:321-322.
    >> Share

  277. SZEPESSY E, Arlett P, Sweeney F, Broich K, et al
    COVID-19 kick-starts a new era for clinical trials and pandemic preparedness in Europe.
    Lancet Infect Dis. 2022;22:315-316.
    >> Share

  278. DEPOORTERE E, Sowinski S, van Hengel A, Kerstiens B, et al
    COVID-19 kick-starts a new era for clinical trials and pandemic preparedness in Europe.
    Lancet Infect Dis. 2022;22:315.
    >> Share

  279. GUPTA S, Saarikko M, Pfutzner A, Raisanen IT, et al
    Compromised periodontal status could increase mortality for patients with COVID-19.
    Lancet Infect Dis. 2022;22:314.
    >> Share

  280. VILLAR JC, Gumisiriza N, Abreu LG, Maude RJ, et al
    Defining post-COVID condition.
    Lancet Infect Dis. 2022;22:316-317.
    >> Share

  281. SCHLAGENHAUF P, Deuel J
    Concerts and COVID: can the beat go on?
    Lancet Infect Dis. 2022;22:299-301.
    >> Share

    February 2022
  282. COBELENS F, Suri RK, Helinski M, Makanga M, et al
    Accelerating research and development of new vaccines against tuberculosis: a global roadmap.
    Lancet Infect Dis. 2022 Feb 28. pii: S1473-3099(21)00810.
    >> Share

  283. VANSHYLLA K, Tober-Lau P, Gruell H, Munn F, et al
    Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults.
    Lancet Infect Dis. 2022 Feb 28. pii: S1473-3099(22)00135.
    >> Share

  284. ABEYWICKREMA M, Goodman AL
    COVID-19 vaccine results might inform malaria vaccine strategies.
    Lancet Infect Dis. 2022 Feb 24. pii: S1473-3099(22)00139.
    >> Share

  285. HART WS, Miller E, Andrews NJ, Waight P, et al
    Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis.
    Lancet Infect Dis. 2022 Feb 14. pii: S1473-3099(22)00001.
    >> Share

  286. YANG Y, Kenah E
    Understanding how fast SARS-CoV-2 variants transmit from household studies.
    Lancet Infect Dis. 2022 Feb 14. pii: S1473-3099(22)00053.
    >> Share

  287. THE LANCET INFECTIOUS DISEASES
    Transitioning to endemicity with COVID-19 research.
    Lancet Infect Dis. 2022 Feb 10. pii: S1473-3099(22)00070.
    >> Share

  288. DOWDY DW
    Has the COVID-19 pandemic increased tuberculosis mortality?
    Lancet Infect Dis. 2022;22:165-166.
    >> Share

    January 2022
  289. MAHMUD-AL-RAFAT A, Hewins B, Mannan A, Kelvin DJ, et al
    COVID-19 vaccine inequity, dependency, and production capability in low-income and middle-income countries: the case of Bangladesh.
    Lancet Infect Dis. 2022 Jan 28. pii: S1473-3099(22)00028.
    >> Share

  290. CANDELLI M
    COVID-19 vaccine: what are we doing and what should we do?
    Lancet Infect Dis. 2022 Jan 27. pii: S1473-3099(22)00003.
    >> Share

  291. CORRAO G, Franchi M, Cereda D, Bortolan F, et al
    Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy.
    Lancet Infect Dis. 2022 Jan 27. pii: S1473-3099(21)00813.
    >> Share

  292. SRIDHAR S, Joaquin A, Bonaparte MI, Bueso A, et al
    Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
    Lancet Infect Dis. 2022 Jan 25. pii: S1473-3099(21)00764.
    >> Share

  293. BURKI T
    The origin of SARS-CoV-2 variants of concern.
    Lancet Infect Dis. 2022 Jan 13. pii: S1473-3099(22)00015.
    >> Share

  294. THE LANCET INFECTIOUS DISEASES
    Time for Africa to future-proof, starting with COVID-19.
    Lancet Infect Dis. 2022 Jan 13. pii: S1473-3099(22)00011.
    >> Share

  295. BURKI T
    COVID-19 vaccine mandates in Europe.
    Lancet Infect Dis. 2022;22:27-28.
    >> Share

  296. LLIBRE JM, Martin-Iguacel R, Revollo B
    Practical measures for SARS-CoV-2 infection prevention - Authors' reply.
    Lancet Infect Dis. 2022;22:21.
    >> Share

  297. FUJIKAWA T
    Practical measures for SARS-CoV-2 infection prevention.
    Lancet Infect Dis. 2022;22:20-21.
    >> Share

  298. CIRILLO N
    Do health-care workers need a COVID-19 vaccine booster?
    Lancet Infect Dis. 2022;22:20.
    >> Share

  299. ROMERO C, Diez JM, Gajardo R
    Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products-an update.
    Lancet Infect Dis. 2022;22:19.
    >> Share

  300. LALVANI A, Hakki S, Singanayagam A, Dunning J, et al
    Transmissibility of SARS-CoV-2 among fully vaccinated individuals - Authors' reply.
    Lancet Infect Dis. 2022;22:18-19.
    >> Share

  301. KO HHT
    Transmissibility of SARS-CoV-2 among fully vaccinated individuals.
    Lancet Infect Dis. 2022;22:17-18.
    >> Share

  302. KNOL MJ, Backer JA, de Melker HE, van den Hof S, et al
    Transmissibility of SARS-CoV-2 among fully vaccinated individuals.
    Lancet Infect Dis. 2022;22:16-17.
    >> Share

  303. FRANCO-PAREDES C
    Transmissibility of SARS-CoV-2 among fully vaccinated individuals.
    Lancet Infect Dis. 2022;22:16.
    >> Share

  304. WU S, Archuleta S, Ming LS, Somani J, et al
    Serial antigen rapid testing in staff of a large acute hospital.
    Lancet Infect Dis. 2022;22:14-15.
    >> Share

    December 2021
  305. SHAPIRO AE, Bender Ignacio RA
    Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19.
    Lancet Infect Dis. 2021 Dec 23. pii: S1473-3099(21)00762.
    >> Share


  306. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.
    Lancet Infect Dis. 2021 Dec 23. pii: S1473-3099(21)00751.
    >> Share

  307. LEWNARD JA, Mahmud A, Narayan T, Wahl B, et al
    All-cause mortality during the COVID-19 pandemic in Chennai, India: an observational study.
    Lancet Infect Dis. 2021 Dec 22. pii: S1473-3099(21)00746.
    >> Share

  308. KUMAR A K A, Mishra N
    Mortality during the COVID-19 pandemic: the blind spots in statistics.
    Lancet Infect Dis. 2021 Dec 22. pii: S1473-3099(21)00767.
    >> Share

  309. GOOSSENS H, Derde L, Horby P, Bonten M, et al
    The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations.
    Lancet Infect Dis. 2021 Dec 21. pii: S1473-3099(21)00705.
    >> Share

  310. SORIANO JB, Murthy S, Marshall JC, Relan P, et al
    A clinical case definition of post-COVID-19 condition by a Delphi consensus.
    Lancet Infect Dis. 2021 Dec 21. pii: S1473-3099(21)00703.
    >> Share

  311. KUMAR RAI G, Saluja T, Chaudhary S, Tamrakar D, et al
    Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
    Lancet Infect Dis. 2021 Dec 20. pii: S1473-3099(21)00455.
    >> Share

  312. THE LANCET INFECTIOUS DISEASES
    Emerging SARS-CoV-2 variants: shooting the messenger.
    Lancet Infect Dis. 2021 Dec 9. pii: S1473-3099(21)00770.
    >> Share

  313. CRODA J, Ranzani OT
    Booster doses for inactivated COVID-19 vaccines: if, when, and for whom.
    Lancet Infect Dis. 2021 Dec 7. pii: S1473-3099(21)00696.
    >> Share

  314. ZENG G, Wu Q, Pan H, Li M, et al
    Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.
    Lancet Infect Dis. 2021 Dec 7. pii: S1473-3099(21)00681.
    >> Share

  315. BAGCCHI S
    Dismal global tuberculosis situation due to COVID-19.
    Lancet Infect Dis. 2021;21:1636.
    >> Share

  316. PICKLES K, Copp T, Dodd RH, Cvejic E, et al
    COVID-19 vaccine intentions in Australia.
    Lancet Infect Dis. 2021;21:1627-1628.
    >> Share

  317. TROSEID M, Hites M, Barratt-Due A, Ader F, et al
    Assessing the evidence on remdesivir.
    Lancet Infect Dis. 2021;21:1630-1631.
    >> Share

  318. EDWARDS B, Biddle N, Gray M, Sollis K, et al
    COVID-19 vaccine intentions in Australia.
    Lancet Infect Dis. 2021;21:1628-1629.
    >> Share

  319. BAST E, Tang F, Dahn J, Palacio A, et al
    Increased risk of hospitalisation and death with the delta variant in the USA.
    Lancet Infect Dis. 2021;21:1629-1630.
    >> Share

  320. BURKI T
    NHS Test and Trace's aims "overstated or not achieved".
    Lancet Infect Dis. 2021;21:1637-1638.
    >> Share

  321. SAMARASEKERA U
    Investigating the origins of novel pathogens.
    Lancet Infect Dis. 2021;21:1633.
    >> Share

  322. THE LANCET INFECTIOUS DISEASES
    Save our only planet.
    Lancet Infect Dis. 2021;21:1613.
    >> Share

  323. ALVAREZ-MORENO C, Cassell JA, Donkor CM, Head MG, et al
    Long-term consequences of the misuse of ivermectin data.
    Lancet Infect Dis. 2021;21:1624-1626.
    >> Share


  324. The value of open-source clinical science in pandemic response: lessons from ISARIC.
    Lancet Infect Dis. 2021;21:1623-1624.
    >> Share

    November 2021
  325. DELAUGERRE C, Foissac F, Abdoul H, Masson G, et al
    Prevention of SARS-CoV-2 transmission during a large, live, indoor gathering (SPRING): a non-inferiority, randomised, controlled trial.
    Lancet Infect Dis. 2021 Nov 26. pii: S1473-3099(21)00673.
    >> Share

  326. THIRUVENGADAM R, Awasthi A, Medigeshi G, Bhattacharya S, et al
    Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
    Lancet Infect Dis. 2021 Nov 25. pii: S1473-3099(21)00680.
    >> Share

  327. WHEATLEY AK, Juno JA
    COVID-19 vaccines in the age of the delta variant.
    Lancet Infect Dis. 2021 Nov 25. pii: S1473-3099(21)00688.
    >> Share

  328. DESAI D, Khan AR, Soneja M, Mittal A, et al
    Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study.
    Lancet Infect Dis. 2021 Nov 23. pii: S1473-3099(21)00674.
    >> Share

  329. THIRUVENGADAM R, Binayke A, Awasthi A
    SARS-CoV-2 delta variant: a persistent threat to the effectiveness of vaccines.
    Lancet Infect Dis. 2021 Nov 23. pii: S1473-3099(21)00697.
    >> Share

  330. KREMSNER PG, Ahuad Guerrero RA, Arana-Arri E, Aroca Martinez GJ, et al
    Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
    Lancet Infect Dis. 2021 Nov 23. pii: S1473-3099(21)00677.
    >> Share

  331. YADAV PD, Kumar S
    Global emergence of SARS-CoV-2 variants: new foresight needed for improved vaccine efficacy.
    Lancet Infect Dis. 2021 Nov 23. pii: S1473-3099(21)00687.
    >> Share

  332. NASA P, Azoulay E, Chakrabarti A, Divatia JV, et al
    Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method.
    Lancet Infect Dis. 2021 Nov 10. pii: S1473-3099(21)00626.
    >> Share

  333. KOJIMA N, Klausner JD
    Protective immunity after recovery from SARS-CoV-2 infection.
    Lancet Infect Dis. 2021 Nov 8. pii: S1473-3099(21)00676.
    >> Share

  334. MAGEE LA, von Dadelszen P, Kalafat E, Duncan EL, et al
    COVID-19 vaccination in pregnancy-number needed to vaccinate to avoid harm.
    Lancet Infect Dis. 2021 Nov 2. pii: S1473-3099(21)00691.
    >> Share

  335. GOMEZ ROMAN R, Tornieporth N, Cherian NG, Shurtleff AC, et al
    Medical countermeasures against henipaviruses: a review and public health perspective.
    Lancet Infect Dis. 2021 Nov 1. pii: S1473-3099(21)00400.
    >> Share

  336. ARORA N, Gudipati A, Kundu R, Prabhakar N, et al
    Post-COVID-19 mucormycosis presenting as chest wall cellulitis with mediastinitis.
    Lancet Infect Dis. 2021;21:1611.
    >> Share

  337. BURKI T
    Increasing COVID-19 vaccine uptake in Black Americans.
    Lancet Infect Dis. 2021;21:1500-1501.
    >> Share

  338. WONG ICK, Wan EYF, Chui CSL, Li X, et al
    Adverse event reporting and Bell's palsy risk after COVID-19 vaccination - Authors' reply.
    Lancet Infect Dis. 2021;21:1492-1493.
    >> Share

  339. CHANG KC, Kong FY
    Adverse event reporting and Bell's palsy risk after COVID-19 vaccination.
    Lancet Infect Dis. 2021;21:1491-1492.
    >> Share

  340. KHOURI C, Roustit M, Cracowski JL
    Adverse event reporting and Bell's palsy risk after COVID-19 vaccination.
    Lancet Infect Dis. 2021;21:1490-1491.
    >> Share

    October 2021
  341. WILDER-SMITH A
    What is the vaccine effect on reducing transmission in the context of the SARS-CoV-2 delta variant?
    Lancet Infect Dis. 2021 Oct 29. pii: S1473-3099(21)00690.
    >> Share

  342. SINGANAYAGAM A, Hakki S, Dunning J, Madon KJ, et al
    Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study.
    Lancet Infect Dis. 2021 Oct 29. pii: S1473-3099(21)00648.
    >> Share

  343. THE LANCET INFECTIOUS DISEASES
    Unmet need for COVID-19 therapies in community settings.
    Lancet Infect Dis. 2021 Oct 14. pii: S1473-3099(21)00633.
    >> Share

  344. SAH P, Moghadas SM, Vilches TN, Shoukat A, et al
    Implications of suboptimal COVID-19 vaccination coverage in Florida and Texas.
    Lancet Infect Dis. 2021 Oct 7. pii: S1473-3099(21)00620.
    >> Share

  345. DEAL A, Halliday R, Crawshaw AF, Hayward SE, et al
    Migration and outbreaks of vaccine-preventable disease in Europe: a systematic review.
    Lancet Infect Dis. 2021 Oct 6. pii: S1473-3099(21)00193.
    >> Share

  346. BURKI T
    Booster shots for COVID-19-the debate continues.
    Lancet Infect Dis. 2021;21:1359-1360.
    >> Share

  347. KIRBY T
    Van-Mai Cao-Lormeau-putting Pacific Islands on the map.
    Lancet Infect Dis. 2021;21:1362.
    >> Share

  348. KENYON G
    Australia's struggle with the delta variant.
    Lancet Infect Dis. 2021;21:1358.
    >> Share

  349. BAGCCHI S
    Infectious diseases in Afghanistan: a dismal scenario.
    Lancet Infect Dis. 2021;21:1357.
    >> Share

  350. VACHARATHIT V, Aiewsakun P, Manopwisedjaroen S, Srisaowakarn C, et al
    CoronaVac induces lower neutralising activity against variants of concern than natural infection.
    Lancet Infect Dis. 2021;21:1352-1354.
    >> Share

  351. AUTZEN B, Dineen K, Vaughan D
    Vaccinating children: fairness and childism.
    Lancet Infect Dis. 2021;21:1354-1355.
    >> Share

  352. CHU CY, Marais G, Opperman C, Doolabh D, et al
    Performance of saliva and mid-turbinate swabs for detection of the beta variant in South Africa.
    Lancet Infect Dis. 2021;21:1354.
    >> Share

    September 2021
  353. SANDMANN FG, Jit M
    Rapid COVID-19 vaccine rollout: immense success but challenges ahead.
    Lancet Infect Dis. 2021 Sep 22. pii: S1473-3099(21)00616.
    >> Share

  354. HAAS EJ, McLaughlin JM, Khan F, Angulo FJ, et al
    Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.
    Lancet Infect Dis. 2021 Sep 22. pii: S1473-3099(21)00566.
    >> Share

  355. KIANG MV, Chin ET, Huynh BQ, Chapman LAC, et al
    Addendum needed on COVID-19 travel study - Authors' reply.
    Lancet Infect Dis. 2021 Sep 15. pii: S1473-3099(21)00562.
    >> Share

  356. ALTENBERG L
    Addendum needed on COVID-19 travel study.
    Lancet Infect Dis. 2021 Sep 15. pii: S1473-3099(21)00454.
    >> Share

  357. XIA S, Zhang Y, Wang Y, Wang H, et al
    Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial.
    Lancet Infect Dis. 2021 Sep 15. pii: S1473-3099(21)00462.
    >> Share

  358. MOSTAGHIMI D, Valdez CN, Larson HT, Kalinich CC, et al
    Prevention of host-to-host transmission by SARS-CoV-2 vaccines.
    Lancet Infect Dis. 2021 Sep 14. pii: S1473-3099(21)00472.
    >> Share

  359. ADER F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, et al
    Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
    Lancet Infect Dis. 2021 Sep 14. pii: S1473-3099(21)00485.
    >> Share

  360. CHOUDHARY OP, Choudhary P, Singh I
    India's COVID-19 vaccination drive: key challenges and resolutions.
    Lancet Infect Dis. 2021 Sep 13. pii: S1473-3099(21)00567.
    >> Share

  361. LACERDA MVG, Bargieri DY
    Protection against COVID-19: beyond antibodies.
    Lancet Infect Dis. 2021 Sep 9. pii: S1473-3099(21)00561.
    >> Share

  362. SAURE D, O'Ryan M, Torres JP, Zuniga M, et al
    Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Lancet Infect Dis. 2021 Sep 9. pii: S1473-3099(21)00479.
    >> Share

  363. JUTHANI PV, Gupta A, Borges KA, Price CC, et al
    Hospitalisation among vaccine breakthrough COVID-19 infections.
    Lancet Infect Dis. 2021 Sep 7. pii: S1473-3099(21)00558.
    >> Share

  364. BAGER P, Wohlfahrt J, Rasmussen M, Albertsen M, et al
    Hospitalisation associated with SARS-CoV-2 delta variant in Denmark.
    Lancet Infect Dis. 2021 Sep 3. pii: S1473-3099(21)00580.
    >> Share

  365. ANTONELLI M, Penfold RS, Merino J, Sudre CH, et al
    Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.
    Lancet Infect Dis. 2021 Sep 1. pii: S1473-3099(21)00460.
    >> Share

  366. BALAKRISHNAN VS
    Memorialising Trump's pandemic (non-)response.
    Lancet Infect Dis. 2021;21:1231.
    >> Share

  367. BAGCCHI S
    Travel notice issued as Venezuela faces health system crisis.
    Lancet Infect Dis. 2021;21:1219.
    >> Share

  368. DE AMBROGI M
    Images of a world facing a pandemic.
    Lancet Infect Dis. 2021;21:1225-1229.
    >> Share

    August 2021
  369. TWOHIG KA, Nyberg T, Zaidi A, Thelwall S, et al
    Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study.
    Lancet Infect Dis. 2021 Aug 27. pii: S1473-3099(21)00475.
    >> Share

  370. LECHIEN JR, Saussez S
    Importance of epidemiological factors in the evaluation of transmissibility and clinical severity of SARS-CoV-2 variants.
    Lancet Infect Dis. 2021 Aug 27. pii: S1473-3099(21)00474.
    >> Share

  371. TEMPE DK
    Is indiscriminate use of medicines the main reason for problems faced during the second wave of COVID-19 in India?
    Lancet Infect Dis. 2021 Aug 24. pii: S1473-3099(21)00450.
    >> Share

  372. BEAUTE J, Adlhoch C, Bundle N, Melidou A, et al
    Testing indicators to monitor the COVID-19 pandemic.
    Lancet Infect Dis. 2021 Aug 24. pii: S1473-3099(21)00461.
    >> Share

  373. UDWADIA Z, Balsari S, Ghafur A
    Is indiscriminate use of medicines the main reason for problems faced during the second wave of COVID-19 in India? - Authors' reply.
    Lancet Infect Dis. 2021 Aug 24. pii: S1473-3099(21)00480.
    >> Share

  374. CIRILLO N, Doan R
    The association between COVID-19 vaccination and Bell's palsy.
    Lancet Infect Dis. 2021 Aug 16. pii: S1473-3099(21)00467.
    >> Share

  375. WAN EYF, Chui CSL, Lai FTT, Chan EWY, et al
    Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study.
    Lancet Infect Dis. 2021 Aug 16. pii: S1473-3099(21)00451.
    >> Share

  376. MORAN E, Cook T, Goodman AL, Gupta RK, et al
    Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials.
    Lancet Infect Dis. 2021 Aug 16. pii: S1473-3099(21)00464.
    >> Share

  377. LI Y, Nair H
    How reliable are COVID-19 burden estimates for India?
    Lancet Infect Dis. 2021 Aug 13. pii: S1473-3099(21)00422.
    >> Share

  378. SNELL LB, Cliff PR, Charalampous T, Alcolea-Medina A, et al
    Rapid genome sequencing in hospitals to identify potential vaccine-escape SARS-CoV-2 variants.
    Lancet Infect Dis. 2021 Aug 13. pii: S1473-3099(21)00482.
    >> Share

  379. LAXMINARAYAN R, B CM, G VT, Arjun Kumar KV, et al
    SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study.
    Lancet Infect Dis. 2021 Aug 13. pii: S1473-3099(21)00393.
    >> Share

  380. THE LANCET INFECTIOUS DISEASES
    COVID-19 vaccine equity and booster doses.
    Lancet Infect Dis. 2021 Aug 12. pii: S1473-3099(21)00486.
    >> Share

  381. KADAMBARI S, Vanderslott S
    Lessons about COVID-19 vaccine hesitancy among minority ethnic people in the UK.
    Lancet Infect Dis. 2021 Aug 9. pii: S1473-3099(21)00404.
    >> Share

  382. TODSEN T, Kirkby N, Benfield T
    Is oropharyngeal sampling a reliable test to detect SARS-CoV-2?
    Lancet Infect Dis. 2021 Aug 4. pii: S1473-3099(21)00395.
    >> Share

  383. TSANG NNY, So HC, Ip DKM
    Is oropharyngeal sampling a reliable test to detect SARS-CoV-2? - Authors' reply.
    Lancet Infect Dis. 2021 Aug 4. pii: S1473-3099(21)00402.
    >> Share

  384. CHEN PZ, Koopmans M, Fisman DN, Gu FX, et al
    Understanding why superspreading drives the COVID-19 pandemic but not the H1N1 pandemic.
    Lancet Infect Dis. 2021 Aug 2. pii: S1473-3099(21)00406.
    >> Share

  385. LONG CM, Marzi A
    Biodefence research two decades on: worth the investment?
    Lancet Infect Dis. 2021;21:e222-e233.
    >> Share

  386. BALAKRISHNAN VS
    Impact of COVID-19 on migrants and refugees.
    Lancet Infect Dis. 2021;21:1076-1077.
    >> Share

  387. ESSO L, Epee E, Bilounga C, Abah A, et al
    Cameroon's bold response to the COVID-19 pandemic during the first and second waves.
    Lancet Infect Dis. 2021;21:1064-1065.
    >> Share

  388. LOTFINEJAD N, Peters A, Tartari E, Fankhauser-Rodriguez C, et al
    Hand hygiene in health care: 20 years of ongoing advances and perspectives.
    Lancet Infect Dis. 2021;21:e209-e221.
    >> Share

  389. KIRBY T
    Akiko Iwasaki-aiming at making vaccines better.
    Lancet Infect Dis. 2021;21:1082.
    >> Share

  390. BURKE MJ, Del Rio C
    Long COVID has exposed medicine's blind-spot.
    Lancet Infect Dis. 2021;21:1062-1064.
    >> Share

    July 2021
  391. TENBUSCH M, Schumacher S, Vogel E, Priller A, et al
    Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2.
    Lancet Infect Dis. 2021 Jul 29. pii: S1473-3099(21)00420.
    >> Share

  392. WU S, Huang J, Zhang Z, Wu J, et al
    Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
    Lancet Infect Dis. 2021 Jul 26. pii: S1473-3099(21)00396.
    >> Share

  393. MOJICA MF, Rossi MA, Vila AJ, Bonomo RA, et al
    The urgent need for metallo-beta-lactamase inhibitors: an unattended global threat.
    Lancet Infect Dis. 2021 Jul 8. pii: S1473-3099(20)30868.
    >> Share

  394. GLYNN JR, Dube A, Fielding K, Crampin AC, et al
    The effect of BCG revaccination on all-cause mortality beyond infancy: 30-year follow-up of a population-based, double-blind, randomised placebo-controlled trial in Malawi.
    Lancet Infect Dis. 2021 Jul 5. pii: S1473-3099(20)30994.
    >> Share

  395. BURKI T
    Global COVID-19 vaccine inequity.
    Lancet Infect Dis. 2021;21:922-923.
    >> Share

  396. ADHIKARI B, Cheah PY
    Vaccine hesitancy in the COVID-19 era.
    Lancet Infect Dis. 2021 Jul 1. pii: S1473-3099(21)00390.
    >> Share

  397. LARKIN M
    Mask confusion in NYC with abrupt CDC guidance changes.
    Lancet Infect Dis. 2021;21:921.
    >> Share

  398. PANDEY A, Galvani AP
    Role of the G20 in safe reopening of international travel.
    Lancet Infect Dis. 2021;21:919.
    >> Share

  399. BAGCCHI S
    Measles immunisation gaps in Africa.
    Lancet Infect Dis. 2021;21:918.
    >> Share

  400. RANA S, Shah R, Ahmed S, Mothabbir G, et al
    Post-disruption catch-up of child immunisation and health-care services in Bangladesh.
    Lancet Infect Dis. 2021;21:913.
    >> Share

    June 2021
  401. GILES B, Meredith P, Robson S, Smith G, et al
    The SARS-CoV-2 B.1.1.7 variant and increased clinical severity-the jury is out.
    Lancet Infect Dis. 2021 Jun 28. pii: S1473-3099(21)00356.
    >> Share

  402. ZOU X, Cao B
    COVID-19 vaccines for children younger than 12 years: are we ready?
    Lancet Infect Dis. 2021 Jun 28. pii: S1473-3099(21)00384.
    >> Share

  403. HAN B, Song Y, Li C, Yang W, et al
    Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.
    Lancet Infect Dis. 2021 Jun 28. pii: S1473-3099(21)00319.
    >> Share

  404. SHROTRI M, Krutikov M, Palmer T, Giddings R, et al
    Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.
    Lancet Infect Dis. 2021 Jun 23. pii: S1473-3099(21)00289.
    >> Share

  405. PRENDECKI M, Willicombe M
    Single-dose SARS-CoV-2 vaccination efficacy in the elderly.
    Lancet Infect Dis. 2021 Jun 23. pii: S1473-3099(21)00354.
    >> Share

  406. HYAMS C, Marlow R, Maseko Z, King J, et al
    Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study.
    Lancet Infect Dis. 2021 Jun 23. pii: S1473-3099(21)00330.
    >> Share

  407. CEVIK M, Mishra S
    SARS-CoV-2 variants and considerations of inferring causality on disease severity.
    Lancet Infect Dis. 2021 Jun 22. pii: S1473-3099(21)00338.
    >> Share

  408. PATONE M, Thomas K, Hatch R, Tan PS, et al
    Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study.
    Lancet Infect Dis. 2021 Jun 22. pii: S1473-3099(21)00318.
    >> Share

  409. BAGER P, Wohlfahrt J, Fonager J, Rasmussen M, et al
    Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study.
    Lancet Infect Dis. 2021 Jun 22. pii: S1473-3099(21)00290.
    >> Share

  410. JENA A
    COVID-19 and SOS tweets in India.
    Lancet Infect Dis. 2021 Jun 21. pii: S1473-3099(21)00355.
    >> Share

  411. THE LANCET INFECTIOUS DISEASES
    Should we vaccinate children against SARS-CoV-2?
    Lancet Infect Dis. 2021 Jun 10. pii: S1473-3099(21)00339.
    >> Share

  412. BALSARI S, Udwadia Z, Shaikh A, Ghafur A, et al
    Contextualising evidence-based recommendations for the second wave of the COVID-19 pandemic in India.
    Lancet Infect Dis. 2021 Jun 8. pii: S1473-3099(21)00329.
    >> Share

  413. OZONOFF A, Nanishi E, Levy O
    Bell's palsy and SARS-CoV-2 vaccines-an unfolding story - Authors' reply.
    Lancet Infect Dis. 2021 Jun 7. pii: S1473-3099(21)00323.
    >> Share

  414. CIRILLO N, Doan R
    Bell's palsy and SARS-CoV-2 vaccines-an unfolding story.
    Lancet Infect Dis. 2021 Jun 7. pii: S1473-3099(21)00273.
    >> Share

  415. MOGHADAS SM, Sah P, Vilches TN, Galvani AP, et al
    Can the USA return to pre-COVID-19 normal by July 4?
    Lancet Infect Dis. 2021 Jun 2. pii: S1473-3099(21)00324.
    >> Share

  416. BURKI T
    HIV in the age of COVID-19.
    Lancet Infect Dis. 2021;21:774-775.
    >> Share

  417. VASAN S, Pitisuttithum P
    Vaccine development lessons between HIV and COVID-19.
    Lancet Infect Dis. 2021;21:759-761.
    >> Share

  418. HOLT E
    Russia's faltering vaccination programme.
    Lancet Infect Dis. 2021;21:772.
    >> Share

  419. KONDRATIUK AL, Pillay TD, Kon OM, Lalvani A, et al
    A conceptual framework to accelerate the clinical impact of evolving research into long COVID.
    Lancet Infect Dis. 2021;21:756-757.
    >> Share

    May 2021
  420. MANDENG N, Fai KN, Bebell LM, Boum Y, et al
    Negative antigen RDT and RT-PCR results do not rule out COVID-19 if clinical suspicion is strong - Authors' reply.
    Lancet Infect Dis. 2021 May 28. pii: S1473-3099(21)00288.
    >> Share

  421. LEKPA FK, Njonnou SRS, Balti E, Luma HN, et al
    Negative antigen RDT and RT-PCR results do not rule out COVID-19 if clinical suspicion is strong.
    Lancet Infect Dis. 2021 May 28. pii: S1473-3099(21)00271.
    >> Share

  422. CHEN Y, Shen H, Huang R, Tong X, et al
    Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac.
    Lancet Infect Dis. 2021 May 27. pii: S1473-3099(21)00287.
    >> Share

  423. REVOLLO B, Blanco I, Soler P, Toro J, et al
    Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial.
    Lancet Infect Dis. 2021 May 27. pii: S1473-3099(21)00268.
    >> Share

  424. PEELING RW, Heymann DL
    Innovations in COVID-19 testing: the road from pandemic response to control.
    Lancet Infect Dis. 2021 May 27. pii: S1473-3099(21)00291.
    >> Share

  425. HUSSAINI SMQ
    A prescription for fair housing during the COVID-19 pandemic.
    Lancet Infect Dis. 2021 May 25. pii: S1473-3099(21)00257.
    >> Share

  426. SIMON F, Watson H, Meynard JB, de Santi VP, et al
    What chikungunya teaches us about COVID-19.
    Lancet Infect Dis. 2021 May 19. pii: S1473-3099(21)00272.
    >> Share

  427. RAMANATHAN M, Ferguson ID, Miao W, Khavari PA, et al
    SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity.
    Lancet Infect Dis. 2021 May 19. pii: S1473-3099(21)00262.
    >> Share

  428. DAL-RE R, Bekker LG, Gluud C, Holm S, et al
    Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities.
    Lancet Infect Dis. 2021 May 18. pii: S1473-3099(21)00263.
    >> Share

  429. THE LANCET INFECTIOUS DISEASES
    The rocky road to universal COVID-19 vaccination.
    Lancet Infect Dis. 2021 May 14. pii: S1473-3099(21)00275.
    >> Share

  430. HUANG L, Cao B
    Post-acute conditions of patients with COVID-19 not requiring hospital admission.
    Lancet Infect Dis. 2021 May 10. pii: S1473-3099(21)00225.
    >> Share

  431. LUND LC, Hallas J, Nielsen H, Koch A, et al
    Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study.
    Lancet Infect Dis. 2021 May 10. pii: S1473-3099(21)00211.
    >> Share

  432. HAMILTON WL, Fieldman T, Jahun A, Warne B, et al
    Applying prospective genomic surveillance to support investigation of hospital-onset COVID-19.
    Lancet Infect Dis. 2021 May 10. pii: S1473-3099(21)00251.
    >> Share

  433. PEELING RW, Olliaro P, Boeras D, Fongwen N, et al
    SARS-CoV-2 rapid antigen detection tests - Authors' reply.
    Lancet Infect Dis. 2021 May 4. pii: S1473-3099(21)00250.
    >> Share

  434. FOUZAS S
    SARS-CoV-2 rapid antigen detection tests.
    Lancet Infect Dis. 2021 May 4. pii: S1473-3099(21)00206.
    >> Share

  435. WEITZEL T, Perez C, Tapia D, Legarraga P, et al
    SARS-CoV-2 rapid antigen detection tests.
    Lancet Infect Dis. 2021 May 4. pii: S1473-3099(21)00249.
    >> Share

  436. SCHINDLER O, Steiner G, Trattner E, Schmon E, et al
    Bilateral infiltrates in a health-care worker during the COVID-19 pandemic.
    Lancet Infect Dis. 2021;21:742.
    >> Share

  437. NORTON A, Olliaro P, Sigfrid L, Carson G, et al
    Long COVID: tackling a multifaceted condition requires a multidisciplinary approach.
    Lancet Infect Dis. 2021;21:601-602.
    >> Share

  438. SCHWARTZ M
    MIS-C: post-infectious syndrome or persistent infection?
    Lancet Infect Dis. 2021;21:e116.
    >> Share

  439. MACKENZIE G
    A year and a day of #Covid19uk tweets.
    Lancet Infect Dis. 2021;21:616.
    >> Share

  440. BURKI T
    Infectious diseases in Yemen.
    Lancet Infect Dis. 2021;21:610-611.
    >> Share

  441. SAMARASEKERA U
    CEPI prepares for future pandemics and epidemics.
    Lancet Infect Dis. 2021;21:608.
    >> Share

  442. BARKSBY R
    1st Women in Malaria conference.
    Lancet Infect Dis. 2021;21:607.
    >> Share

  443. SIE A, Hanefeld J, Chaponda M, Chico RM, et al
    Congenital malformations in sub-Saharan Africa-warnings of a silent epidemic?
    Lancet Infect Dis. 2021;21:594-596.
    >> Share

    April 2021
  444. DRURY RE, O'Connor D
    Symptom study app provides real-world data on COVID-19 vaccines.
    Lancet Infect Dis. 2021 Apr 27. pii: S1473-3099(21)00264.
    >> Share

  445. MENNI C, Klaser K, May A, Polidori L, et al
    Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.
    Lancet Infect Dis. 2021 Apr 27. pii: S1473-3099(21)00224.
    >> Share

  446. GILBERT SC, Lambe T
    Recombinant protein vaccines against SARS-CoV-2.
    Lancet Infect Dis. 2021 Apr 19. pii: S1473-3099(21)00227.
    >> Share

  447. GOEPFERT PA, Fu B, Chabanon AL, Bonaparte MI, et al
    Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.
    Lancet Infect Dis. 2021 Apr 19. pii: S1473-3099(21)00147.
    >> Share

  448. CHAPPELL KJ, Mordant FL, Li Z, Wijesundara DK, et al
    Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Lancet Infect Dis. 2021 Apr 19. pii: S1473-3099(21)00200.
    >> Share

  449. OBARO S
    COVID-19 herd immunity by immunisation: are children in the herd?
    Lancet Infect Dis. 2021 Apr 19. pii: S1473-3099(21)00212.
    >> Share

  450. SPINELLI MA, Rutherford G, Gandhi M
    Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases - Authors' reply.
    Lancet Infect Dis. 2021 Apr 14. pii: S1473-3099(21)00210.
    >> Share

  451. TRUNFIO M, Calcagno A, Bonora S, Di Perri G, et al
    Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases.
    Lancet Infect Dis. 2021 Apr 14. pii: S1473-3099(21)00205.
    >> Share

  452. THOMPSON RN, Hill EM, Gog JR
    SARS-CoV-2 incidence and vaccine escape.
    Lancet Infect Dis. 2021 Apr 13. pii: S1473-3099(21)00202.
    >> Share

  453. BOUM Y, Eyangoh S, Okomo MC
    Beyond COVID-19-will self-sampling and testing become the norm?
    Lancet Infect Dis. 2021 Apr 12. pii: S1473-3099(21)00197.
    >> Share

  454. ONG SWX, Young BE, Lye DC
    Lack of detail in population-level data impedes analysis of SARS-CoV-2 variants of concern and clinical outcomes.
    Lancet Infect Dis. 2021 Apr 12. pii: S1473-3099(21)00201.
    >> Share

  455. FRAMPTON D, Rampling T, Cross A, Bailey H, et al
    Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study.
    Lancet Infect Dis. 2021 Apr 12. pii: S1473-3099(21)00170.
    >> Share

  456. TSANG NNY, So HC, Ng KY, Cowling BJ, et al
    Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis.
    Lancet Infect Dis. 2021 Apr 12. pii: S1473-3099(21)00146.
    >> Share

  457. THE LANCET INFECTIOUS DISEASES
    "In an ocean of ashes, islands of order": WHO's SARS-CoV-2 origin report.
    Lancet Infect Dis. 2021 Apr 9. pii: S1473-3099(21)00213.
    >> Share

  458. HOLT E
    COVID-19 vaccination in Ukraine.
    Lancet Infect Dis. 2021;21:462.
    >> Share

  459. ADEPOJU P
    Ebola and COVID-19 in DR Congo and Guinea.
    Lancet Infect Dis. 2021;21:461.
    >> Share

  460. BURKI T
    Behind Cuba's successful pandemic response.
    Lancet Infect Dis. 2021;21:465-466.
    >> Share

  461. KENYON G
    Vacuna-gate escalates in Peru.
    Lancet Infect Dis. 2021;21:463.
    >> Share

  462. THE LANCET INFECTIOUS DISEASES
    A glimmer of hope beyond the spring for Europe.
    Lancet Infect Dis. 2021;21:439.
    >> Share

  463. JOMBART T
    Why development of outbreak analytics tools should be valued, supported, and funded.
    Lancet Infect Dis. 2021;21:458-459.
    >> Share

    March 2021
  464. JENTSCH PC, Anand M, Bauch CT
    Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study.
    Lancet Infect Dis. 2021 Mar 31. pii: S1473-3099(21)00057.
    >> Share

  465. WELLS CR, Galvani AP
    The interplay between COVID-19 restrictions and vaccination.
    Lancet Infect Dis. 2021 Mar 31. pii: S1473-3099(21)00074.
    >> Share

  466. MAHARAJ AS, Parker J, Hopkins JP, Gournis E, et al
    The effect of seasonal respiratory virus transmission on syndromic surveillance for COVID-19 in Ontario, Canada.
    Lancet Infect Dis. 2021 Mar 25. pii: S1473-3099(21)00151.
    >> Share

  467. BOUM Y, Fai KN, Nicolay B, Mboringong AB, et al
    Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study.
    Lancet Infect Dis. 2021 Mar 25. pii: S1473-3099(21)00132.
    >> Share

  468. PEELING RW, Olliaro P
    Rolling out COVID-19 antigen rapid diagnostic tests: the time is now.
    Lancet Infect Dis. 2021 Mar 25. pii: S1473-3099(21)00152.
    >> Share

  469. IVERSEN PL, Bavari S
    Is there space for a three-dose vaccine to fight the spread of SARS-CoV-2?
    Lancet Infect Dis. 2021 Mar 24. pii: S1473-3099(21)00149.
    >> Share

  470. YANG S, Li Y, Dai L, Wang J, et al
    Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Lancet Infect Dis. 2021 Mar 24. pii: S1473-3099(21)00127.
    >> Share

  471. KIANG MV, Chin ET, Huynh BQ, Chapman LAC, et al
    Routine asymptomatic testing strategies for airline travel during the COVID-19 pandemic: a simulation study.
    Lancet Infect Dis. 2021 Mar 22. pii: S1473-3099(21)00134.
    >> Share

  472. GUILAMO-RAMOS V, Thimm-Kaiser M, Benzekri A, Hidalgo A, et al
    Nurses at the frontline of public health emergency preparedness and response: lessons learned from the HIV/AIDS pandemic and emerging infectious disease outbreaks.
    Lancet Infect Dis. 2021 Mar 18. pii: S1473-3099(20)30983.
    >> Share

  473. MACINTYRE CR
    Navigating post-vaccine COVID-19 futures in the health and economic context.
    Lancet Infect Dis. 2021 Mar 18. pii: S1473-3099(21)00126.
    >> Share

  474. CONTRERAS S, Priesemann V
    Risking further COVID-19 waves despite vaccination.
    Lancet Infect Dis. 2021 Mar 18. pii: S1473-3099(21)00167.
    >> Share

  475. MOORE S, Hill EM, Tildesley MJ, Dyson L, et al
    Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study.
    Lancet Infect Dis. 2021 Mar 18. pii: S1473-3099(21)00143.
    >> Share

  476. SANDMANN FG, Davies NG, Vassall A, Edmunds WJ, et al
    The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.
    Lancet Infect Dis. 2021 Mar 18. pii: S1473-3099(21)00079.
    >> Share

  477. NICOLAS D, Coloma E, Pericas JM
    Alternatives to conventional hospitalisation that enhance health systems' capacity to treat COVID-19.
    Lancet Infect Dis. 2021 Mar 9. pii: S1473-3099(21)00093.
    >> Share

  478. VAN GEMERT C, Tapo PS, Sero K
    Border screening is an essential component of COVID-19 testing strategies in Vanuatu.
    Lancet Infect Dis. 2021 Mar 8. pii: S1473-3099(21)00135.
    >> Share

  479. ELLA R, Reddy S, Jogdand H, Sarangi V, et al
    Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.
    Lancet Infect Dis. 2021 Mar 8. pii: S1473-3099(21)00070.
    >> Share

  480. LI JX, Zhu FC
    Adjuvantation helps to optimise COVID-19 vaccine candidate.
    Lancet Infect Dis. 2021 Mar 8. pii: S1473-3099(21)00094.
    >> Share

  481. MEHTA P, Bunker CB, Ciurtin C, Porter JC, et al
    Chilblain-like acral lesions in long COVID-19: management and implications for understanding microangiopathy.
    Lancet Infect Dis. 2021 Mar 8. pii: S1473-3099(21)00133.
    >> Share

  482. VAN DIJCK C, Tsoumanis A, Rotsaert A, Vuylsteke B, et al
    Antibacterial mouthwash to prevent sexually transmitted infections in men who have sex with men taking HIV pre-exposure prophylaxis (PReGo): a randomised, placebo-controlled, crossover trial.
    Lancet Infect Dis. 2021 Mar 4. pii: S1473-3099(20)30778.
    >> Share

  483. BURKI T
    COVID-19 among American Indians and Alaska Natives.
    Lancet Infect Dis. 2021;21:325-326.
    >> Share

  484. SAMARASEKERA U
    Feelings towards COVID-19 vaccination in Africa.
    Lancet Infect Dis. 2021;21:324.
    >> Share

  485. BAGCCHI S
    The world's largest COVID-19 vaccination campaign.
    Lancet Infect Dis. 2021;21:323.
    >> Share

  486. PERMPALUNG N, Maertens J, Marr KA
    Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis.
    Lancet Infect Dis. 2021 Mar 1. pii: S1473-3099(21)00060.
    >> Share

  487. JABEEN K, Farooqi J, Irfan M, Ali SA, et al
    Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis.
    Lancet Infect Dis. 2021 Mar 1. pii: S1473-3099(21)00066.
    >> Share

  488. DROZD M, Pujades-Rodriguez M, Lillie PJ, Straw S, et al
    Non-communicable disease, sociodemographic factors, and risk of death from infection: a UK Biobank observational cohort study.
    Lancet Infect Dis. 2021 Mar 1. pii: S1473-3099(20)30978.
    >> Share

  489. KOEHLER P, White PL, Verweij PE, Cornely OA, et al
    Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis - Authors' reply.
    Lancet Infect Dis. 2021 Mar 1. pii: S1473-3099(21)00123.
    >> Share

  490. TARANTOLA A, Gautier L
    Biostatistics to better detect fishy findings.
    Lancet Infect Dis. 2021;21:316-317.
    >> Share

    February 2021
  491. OZONOFF A, Nanishi E, Levy O
    Bell's palsy and SARS-CoV-2 vaccines.
    Lancet Infect Dis. 2021 Feb 24. pii: S1473-3099(21)00076.
    >> Share

  492. DARMON M, Dumas G
    Anticipating outcomes for patients with COVID-19 and identifying prognosis patterns.
    Lancet Infect Dis. 2021 Feb 23. pii: S1473-3099(21)00073.
    >> Share

  493. PEELING RW, Olliaro PL, Boeras DI, Fongwen N, et al
    Scaling up COVID-19 rapid antigen tests: promises and challenges.
    Lancet Infect Dis. 2021 Feb 23. pii: S1473-3099(21)00048.
    >> Share

  494. GUTIERREZ-GUTIERREZ B, Del Toro MD, Borobia AM, Carcas A, et al
    Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study.
    Lancet Infect Dis. 2021 Feb 23. pii: S1473-3099(21)00019.
    >> Share

  495. SPINELLI MA, Glidden DV, Gennatas ED, Bielecki M, et al
    Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity.
    Lancet Infect Dis. 2021 Feb 22. pii: S1473-3099(20)30982.
    >> Share

  496. OLLIARO P
    What does 95% COVID-19 vaccine efficacy really mean?
    Lancet Infect Dis. 2021 Feb 17. pii: S1473-3099(21)00075.
    >> Share

  497. ROMERO C, Diez JM, Gajardo R
    Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products.
    Lancet Infect Dis. 2021 Feb 16. pii: S1473-3099(21)00059.
    >> Share

  498. GHAFARI M, Kadivar A, Katzourakis A
    Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran.
    Lancet Infect Dis. 2021 Feb 15. pii: S1473-3099(21)00053.
    >> Share

  499. NAZEMIPOUR M, Shakiba M, Mansournia MA
    Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran.
    Lancet Infect Dis. 2021 Feb 15. pii: S1473-3099(21)00044.
    >> Share

  500. DARVISHIAN M, Sharafkhah M, Poustchi H, Malekzadeh R, et al
    Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran - Authors' reply.
    Lancet Infect Dis. 2021 Feb 15. pii: S1473-3099(21)00058.
    >> Share

  501. INZAULE SC, Tessema SK, Kebede Y, Ogwell Ouma AE, et al
    Genomic-informed pathogen surveillance in Africa: opportunities and challenges.
    Lancet Infect Dis. 2021 Feb 12. pii: S1473-3099(20)30939.
    >> Share

  502. THE LANCET INFECTIOUS DISEASES
    The COVID-19 exit strategy-why we need to aim low.
    Lancet Infect Dis. 2021 Feb 11. pii: S1473-3099(21)00080.
    >> Share

  503. ALAM I, Radovanovic A, Incitti R, Kamau AA, et al
    CovMT: an interactive SARS-CoV-2 mutation tracker, with a focus on critical variants.
    Lancet Infect Dis. 2021 Feb 8. pii: S1473-3099(21)00078.
    >> Share

  504. IVERSEN PL, Bavari S
    Inactivated COVID-19 vaccines to make a global impact.
    Lancet Infect Dis. 2021 Feb 3. pii: S1473-3099(21)00020.
    >> Share

  505. FAIRGRIEVE D, Holm S, Howells G, Kirchhelle C, et al
    In favour of a bespoke COVID-19 vaccines compensation scheme.
    Lancet Infect Dis. 2021 Feb 3. pii: S1473-3099(21)00065.
    >> Share

  506. WU Z, Hu Y, Xu M, Chen Z, et al
    Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Lancet Infect Dis. 2021 Feb 3. pii: S1473-3099(20)30987.
    >> Share

  507. CORNELISSEN L, Andre E
    Understanding the drivers of transmission of SARS-CoV-2.
    Lancet Infect Dis. 2021 Feb 2. pii: S1473-3099(21)00005.
    >> Share

  508. MARKS M, Millat-Martinez P, Ouchi D, Roberts CH, et al
    Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study.
    Lancet Infect Dis. 2021 Feb 2. pii: S1473-3099(20)30985.
    >> Share

  509. STRINGHINI S, Zaballa ME, Perez-Saez J, Pullen N, et al
    Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak.
    Lancet Infect Dis. 2021 Feb 1. pii: S1473-3099(21)00054.
    >> Share

  510. BURKI T
    The elusive elimination of river blindness.
    Lancet Infect Dis. 2021;21:175-176.
    >> Share

  511. MAKONI M
    New tuberculosis tests and drugs remain out of reach.
    Lancet Infect Dis. 2021;21:174.
    >> Share

  512. THE LANCET INFECTIOUS DISEASES
    An exceptional vaccination policy in exceptional circumstances.
    Lancet Infect Dis. 2021;21:149.
    >> Share

  513. MANTHA S
    Ratio, rate, or risk?
    Lancet Infect Dis. 2021;21:165-166.
    >> Share

  514. BAUCH CT
    Estimating the COVID-19 R number: a bargain with the devil?
    Lancet Infect Dis. 2021;21:151-153.
    >> Share

  515. LI Y, Campbell H, Kulkarni D, Harpur A, et al
    The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries.
    Lancet Infect Dis. 2021;21:193-202.
    >> Share

    January 2021
  516. MOHAPATRA PR, Mishra B
    Regulatory approval of COVID-19 vaccine for restricted use in clinical trial mode.
    Lancet Infect Dis. 2021 Jan 25. pii: S1473-3099(21)00045.
    >> Share

  517. ELLA R, Vadrevu KM, Jogdand H, Prasad S, et al
    Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.
    Lancet Infect Dis. 2021 Jan 21. pii: S1473-3099(20)30942.
    >> Share

  518. ROSTAD CA, Anderson EJ
    Optimism and caution for an inactivated COVID-19 vaccine.
    Lancet Infect Dis. 2021 Jan 21. pii: S1473-3099(20)30988.
    >> Share

  519. PALLETT SJC, Jones R, Randell P, Davies GW, et al
    Structured serological testing is an essential component to investigating SARS-CoV-2 reinfection.
    Lancet Infect Dis. 2021 Jan 20. pii: S1473-3099(20)30990.
    >> Share

  520. GARDNER AR
    COVID-19 through the Latinx infectious disease doctor's eyes.
    Lancet Infect Dis. 2021 Jan 19. pii: S1473-3099(20)30885.
    >> Share

  521. LI F, Li YY, Liu MJ, Fang LQ, et al
    Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study.
    Lancet Infect Dis. 2021 Jan 18. pii: S1473-3099(20)30981.
    >> Share

  522. MCMAHON DE, Gallman AE, Hruza GJ, Rosenbach M, et al
    Long COVID in the skin: a registry analysis of COVID-19 dermatological duration.
    Lancet Infect Dis. 2021 Jan 15. pii: S1473-3099(20)30986.
    >> Share

  523. JARCHOW-MACDONALD AA, Burns R, Miller J, Kerr L, et al
    Keeping childhood immunisation rates stable during the COVID-19 pandemic.
    Lancet Infect Dis. 2021 Jan 15. pii: S1473-3099(20)30991.
    >> Share

  524. FIORENTINI S, Messali S, Zani A, Caccuri F, et al
    First detection of SARS-CoV-2 spike protein N501 mutation in Italy in August, 2020.
    Lancet Infect Dis. 2021 Jan 12. pii: S1473-3099(21)00007.
    >> Share

  525. ROTHE C
    Multiple testing and the effect of NPIs on the spread of SARS-CoV-2.
    Lancet Infect Dis. 2021 Jan 6. pii: S1473-3099(20)30935.
    >> Share

  526. BURKI T
    Equitable distribution of COVID-19 vaccines.
    Lancet Infect Dis. 2021;21:33-34.
    >> Share

  527. HOLT E
    COVID-19 testing in Slovakia.
    Lancet Infect Dis. 2021;21:32.
    >> Share

  528. THE LANCET INFECTIOUS DISEASES
    Tuberculosis and malaria in the age of COVID-19.
    Lancet Infect Dis. 2021;21:1.
    >> Share

    December 2020
  529. DAVIES NG, Barnard RC, Jarvis CI, Russell TW, et al
    Association of tiered restrictions and a second lockdown with COVID-19 deaths and hospital admissions in England: a modelling study.
    Lancet Infect Dis. 2020 Dec 23. pii: S1473-3099(20)30984.
    >> Share

  530. HENGEL B, Causer L, Matthews S, Smith K, et al
    A decentralised point-of-care testing model to address inequities in the COVID-19 response.
    Lancet Infect Dis. 2020 Dec 23. pii: S1473-3099(20)30859.
    >> Share

  531. SAMER C, Lacombe K, Calmy A
    Cyber harassment of female scientists will not be the new norm.
    Lancet Infect Dis. 2020 Dec 23. pii: S1473-3099(20)30944.
    >> Share

  532. DUYSBURGH E, Mortgat L, Barbezange C, Dierick K, et al
    Persistence of IgG response to SARS-CoV-2.
    Lancet Infect Dis. 2020 Dec 17. pii: S1473-3099(20)30943.
    >> Share

  533. POUSTCHI H, Darvishian M, Mohammadi Z, Shayanrad A, et al
    SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
    Lancet Infect Dis. 2020 Dec 15. pii: S1473-3099(20)30858.
    >> Share

  534. DODD RH, Pickles K, Nickel B, Cvejic E, et al
    Concerns and motivations about COVID-19 vaccination.
    Lancet Infect Dis. 2020 Dec 15. pii: S1473-3099(20)30926.
    >> Share

  535. KOEHLER P, Bassetti M, Chakrabarti A, Chen SCA, et al
    Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.
    Lancet Infect Dis. 2020 Dec 14. pii: S1473-3099(20)30847.
    >> Share

  536. ALLISON J, Badanjak S, Bach B, Bell C, et al
    An interactive tracker for ceasefires in the time of COVID-19.
    Lancet Infect Dis. 2020 Dec 14. pii: S1473-3099(20)30932.
    >> Share

  537. FLASCHE S, Edmunds WJ
    The role of schools and school-aged children in SARS-CoV-2 transmission.
    Lancet Infect Dis. 2020 Dec 8. pii: S1473-3099(20)30927.
    >> Share

  538. ISMAIL SA, Saliba V, Lopez Bernal J, Ramsay ME, et al
    SARS-CoV-2 infection and transmission in educational settings: a prospective, cross-sectional analysis of infection clusters and outbreaks in England.
    Lancet Infect Dis. 2020 Dec 8. pii: S1473-3099(20)30882.
    >> Share

  539. SINGH JA, Upshur REG
    The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials.
    Lancet Infect Dis. 2020 Dec 8. pii: S1473-3099(20)30923.
    >> Share

  540. MARSHALL JC, Murthy S, Diaz J
    Fungal infections should be part of the core outcome set for COVID-19 - Authors' reply.
    Lancet Infect Dis. 2020 Dec 7. pii: S1473-3099(20)30681.
    >> Share

  541. VERWEIJ PE, Alanio A
    Fungal infections should be part of the core outcome set for COVID-19.
    Lancet Infect Dis. 2020 Dec 7. pii: S1473-3099(20)30591.
    >> Share

  542. BROWN RCH, Savulescu J, Kelly D, Wilkinson D, et al
    A public health ethic should inform policies on COVID-19 immunity passports - Authors' reply.
    Lancet Infect Dis. 2020 Dec 7. pii: S1473-3099(20)30922.
    >> Share

  543. BAYLIS F, Kofler N
    A public health ethic should inform policies on COVID-19 immunity passports.
    Lancet Infect Dis. 2020 Dec 7. pii: S1473-3099(20)30918.
    >> Share

  544. MEYEROWITZ EA, Richterman A, Bogoch II, Low N, et al
    Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2.
    Lancet Infect Dis. 2020 Dec 7. pii: S1473-3099(20)30837.
    >> Share

  545. ARMITAGE R, Nellums LB
    Antibiotic prescribing in general practice during COVID-19.
    Lancet Infect Dis. 2020 Dec 1. pii: S1473-3099(20)30917.
    >> Share

  546. KAZI F, Mushtaq A
    IDWeek 2020.
    Lancet Infect Dis. 2020;20:1374.
    >> Share

    November 2020
  547. YOUNG B, Tan TT, Leo YS
    The place for remdesivir in COVID-19 treatment.
    Lancet Infect Dis. 2020 Nov 26. pii: S1473-3099(20)30911.
    >> Share

  548. PRADO-VIVAR B, Becerra-Wong M, Guadalupe JJ, Marquez S, et al
    A case of SARS-CoV-2 reinfection in Ecuador.
    Lancet Infect Dis. 2020 Nov 23. pii: S1473-3099(20)30910.
    >> Share

  549. KOOPMANS M
    SARS-CoV-2 and the human-animal interface: outbreaks on mink farms.
    Lancet Infect Dis. 2020 Nov 20. pii: S1473-3099(20)30912.
    >> Share

  550. KAMPF G, Lemmen S, Suchomel M
    Ct values and infectivity of SARS-CoV-2 on surfaces.
    Lancet Infect Dis. 2020 Nov 19. pii: S1473-3099(20)30883.
    >> Share

  551. ROARTY C, Tonry C, McFetridge L, Mitchell H, et al
    Kinetics and seroprevalence of SARS-CoV-2 antibodies in children.
    Lancet Infect Dis. 2020 Nov 19. pii: S1473-3099(20)30884.
    >> Share

  552. BAR-ZEEV N, Kochhar S
    Expecting the unexpected with COVID-19 vaccines.
    Lancet Infect Dis. 2020 Nov 17. pii: S1473-3099(20)30870.
    >> Share

  553. ZHANG Y, Zeng G, Pan H, Li C, et al
    Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Lancet Infect Dis. 2020 Nov 17. pii: S1473-3099(20)30843.
    >> Share

  554. PEIFFER-SMADJA N, Rebeaud ME, Guihur A, Mahamat-Saleh Y, et al
    Hydroxychloroquine and COVID-19: a tale of populism and obscurantism.
    Lancet Infect Dis. 2020 Nov 13. pii: S1473-3099(20)30866.
    >> Share

  555. NG OT, Marimuthu K, Koh V, Pang J, et al
    SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study.
    Lancet Infect Dis. 2020 Nov 2. pii: S1473-3099(20)30833.
    >> Share

  556. BADR HS, Gardner LM
    Limitations of using mobile phone data to model COVID-19 transmission in the USA.
    Lancet Infect Dis. 2020 Nov 2. pii: S1473-3099(20)30861.
    >> Share

  557. KIRBY T
    Matshidiso Moeti, first female WHO Regional Director.
    Lancet Infect Dis. 2020;20:1244.
    >> Share

  558. MUSHTAQ A, Kazi F
    New guidelines to treat bacterial infections.
    Lancet Infect Dis. 2020;20:1239.
    >> Share

  559. JESUDASON T
    The 11th annual NTD NGO Network conference.
    Lancet Infect Dis. 2020;20:1238.
    >> Share

    October 2020
  560. IVERSEN K, Bundgaard H, Harritshoj L, Ullum H, et al
    Specificity and cross-reactivity of a test for anti-SARS-CoV-2 antibodies - Authors' reply.
    Lancet Infect Dis. 2020 Oct 30. pii: S1473-3099(20)30849.
    >> Share

  561. CHOY KW
    Specificity and cross-reactivity of a test for anti-SARS-CoV-2 antibodies.
    Lancet Infect Dis. 2020 Oct 30. pii: S1473-3099(20)30787.
    >> Share

  562. VAN ELSLANDE J, Andre E, Van Ranst M, Lagrou K, et al
    Immunoassays for anti-SARS-CoV-2 antibodies: recent insights.
    Lancet Infect Dis. 2020 Oct 30. pii: S1473-3099(20)30846.
    >> Share

  563. HODGSON SH, Mansatta K, Mallett G, Harris V, et al
    What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.
    Lancet Infect Dis. 2020 Oct 27. pii: S1473-3099(20)30773.
    >> Share

  564. YANG W, Kandula S, Huynh M, Greene SK, et al
    Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis.
    Lancet Infect Dis. 2020 Oct 19. pii: S1473-3099(20)30769.
    >> Share

  565. BROWN RCH, Kelly D, Wilkinson D, Savulescu J, et al
    The scientific and ethical feasibility of immunity passports.
    Lancet Infect Dis. 2020 Oct 16. pii: S1473-3099(20)30766.
    >> Share

  566. ISAKOVA-SIVAK I, Rudenko L
    A promising inactivated whole-virion SARS-CoV-2 vaccine.
    Lancet Infect Dis. 2020 Oct 15. pii: S1473-3099(20)30832.
    >> Share

  567. XIA S, Zhang Y, Wang Y, Wang H, et al
    Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
    Lancet Infect Dis. 2020 Oct 15. pii: S1473-3099(20)30831.
    >> Share

  568. TILLETT RL, Sevinsky JR, Hartley PD, Kerwin H, et al
    Genomic evidence for reinfection with SARS-CoV-2: a case study.
    Lancet Infect Dis. 2020 Oct 12. pii: S1473-3099(20)30764.
    >> Share

  569. IWASAKI A
    What reinfections mean for COVID-19.
    Lancet Infect Dis. 2020 Oct 12. pii: S1473-3099(20)30783.
    >> Share

  570. VEHRESCHILD MJGT, Tacconelli E, Giske CG, Peschel A, et al
    Beyond COVID-19-a paradigm shift in infection management?
    Lancet Infect Dis. 2020 Oct 9. pii: S1473-3099(20)30789.
    >> Share

  571. THE LANCET INFECTIOUS DISEASES
    The intersection of COVID-19 and mental health.
    Lancet Infect Dis. 2020 Oct 8. pii: S1473-3099(20)30797.
    >> Share

  572. BURKI T
    China's successful control of COVID-19.
    Lancet Infect Dis. 2020 Oct 8. pii: S1473-3099(20)30800.
    >> Share

  573. PERLMAN S, Zumla A
    MERS-CoV in Africa-an enigma with relevance to COVID-19.
    Lancet Infect Dis. 2020 Oct 6. pii: S1473-3099(20)30578.
    >> Share

  574. MOK CKP, Zhu A, Zhao J, Lau EHY, et al
    T-cell responses to MERS coronavirus infection in people with occupational exposure to dromedary camels in Nigeria: an observational cohort study.
    Lancet Infect Dis. 2020 Oct 6. pii: S1473-3099(20)30599.
    >> Share

  575. KHALIL A, von Dadelszen P, Kalafat E, Sebghati M, et al
    Change in obstetric attendance and activities during the COVID-19 pandemic.
    Lancet Infect Dis. 2020 Oct 5. pii: S1473-3099(20)30779.
    >> Share

  576. GALVAO J
    COVID-19: the deadly threat of misinformation.
    Lancet Infect Dis. 2020 Oct 5. pii: S1473-3099(20)30721.
    >> Share

  577. BURKI T
    COVID-19 claims another victim.
    Lancet Infect Dis. 2020;20:1129-1130.
    >> Share

  578. MAKONI M
    COVID-19 in Africa: half a year later.
    Lancet Infect Dis. 2020;20:1127.
    >> Share

  579. RATHI S, Ish P, Kalantri A, Kalantri S, et al
    Hydroxychloroquine prophylaxis for COVID-19 contacts in India.
    Lancet Infect Dis. 2020;20:1118-1119.
    >> Share

  580. PRINCIPI N, Esposito S
    Chloroquine or hydroxychloroquine for prophylaxis of COVID-19.
    Lancet Infect Dis. 2020;20:1118.
    >> Share

  581. KIRBY T
    Evelina Tacconelli-two viruses, two wars.
    Lancet Infect Dis. 2020;20:1132.
    >> Share

  582. BALAKRISHNAN VS
    The arrival of Sputnik V.
    Lancet Infect Dis. 2020;20:1128.
    >> Share

    September 2020
  583. FRANCO-PAREDES C, Ghandnoosh N, Latif H, Krsak M, et al
    Decarceration and community re-entry in the COVID-19 era.
    Lancet Infect Dis. 2020 Sep 29. pii: S1473-3099(20)30730.
    >> Share

  584. MONDELLI MU, Colaneri M, Seminari EM, Baldanti F, et al
    Low risk of SARS-CoV-2 transmission by fomites in real-life conditions.
    Lancet Infect Dis. 2020 Sep 29. pii: S1473-3099(20)30678.
    >> Share


  585. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison.
    Lancet Infect Dis. 2020 Sep 23. pii: S1473-3099(20)30634.
    >> Share

  586. HOULIHAN CF, Beale R
    The complexities of SARS-CoV-2 serology.
    Lancet Infect Dis. 2020 Sep 23. pii: S1473-3099(20)30699.
    >> Share

  587. TEBOH-EWUNGKEM MI, Ngwa GA
    COVID-19 in malaria-endemic regions: potential consequences for malaria intervention coverage, morbidity, and mortality.
    Lancet Infect Dis. 2020 Sep 21. pii: S1473-3099(20)30763.
    >> Share

  588. WEISS DJ, Bertozzi-Villa A, Rumisha SF, Amratia P, et al
    Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis.
    Lancet Infect Dis. 2020 Sep 21. pii: S1473-3099(20)30700.
    >> Share

  589. GATALO O, Tseng K, Hamilton A, Lin G, et al
    Associations between phone mobility data and COVID-19 cases.
    Lancet Infect Dis. 2020 Sep 15. pii: S1473-3099(20)30725.
    >> Share

  590. RHODES A, Hoq M, Measey MA, Danchin M, et al
    Intention to vaccinate against COVID-19 in Australia.
    Lancet Infect Dis. 2020 Sep 14. pii: S1473-3099(20)30724.
    >> Share

  591. BAX A, Bax CE, Stadnytskyi V, Anfinrud P, et al
    SARS-CoV-2 transmission via speech-generated respiratory droplets.
    Lancet Infect Dis. 2020 Sep 11. pii: S1473-3099(20)30726.
    >> Share

  592. THE LANCET INFECTIOUS DISEASES
    Curing COVID-19.
    Lancet Infect Dis. 2020 Sep 10. pii: S1473-3099(20)30706.
    >> Share

  593. THE LANCET INFECTIOUS DISEASES
    Air travel in the time of COVID-19.
    Lancet Infect Dis. 2020;20:993.
    >> Share

  594. BURKI T
    The origin of SARS-CoV-2.
    Lancet Infect Dis. 2020;20:1018-1019.
    >> Share

  595. YELIN D, Wirtheim E, Vetter P, Kalil AC, et al
    Long-term consequences of COVID-19: research needs.
    Lancet Infect Dis. 2020 Sep 1. pii: S1473-3099(20)30701.
    >> Share

    August 2020
  596. GRASSLY NC, Pons-Salort M, Parker EPK, White PJ, et al
    Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study.
    Lancet Infect Dis. 2020 Aug 18. pii: S1473-3099(20)30630.
    >> Share

  597. JIANG L, Tang K, Levin M, Irfan O, et al
    COVID-19 and multisystem inflammatory syndrome in children and adolescents.
    Lancet Infect Dis. 2020 Aug 17. pii: S1473-3099(20)30651.
    >> Share

  598. JAVELLE E, Raoult D
    COVID-19 pandemic more than a century after the Spanish flu.
    Lancet Infect Dis. 2020 Aug 11. pii: S1473-3099(20)30650.
    >> Share

  599. HEATH PT, Le Doare K, Khalil A
    Inclusion of pregnant women in COVID-19 vaccine development.
    Lancet Infect Dis. 2020 Aug 11. pii: S1473-3099(20)30638.
    >> Share

  600. MANHEIM D
    Evolving ethics of COVID-19 challenge trials.
    Lancet Infect Dis. 2020 Aug 11. pii: S1473-3099(20)30649.
    >> Share

  601. STANDL F, Jockel KH, Brune B, Schmidt B, et al
    Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics.
    Lancet Infect Dis. 2020 Aug 11. pii: S1473-3099(20)30648.
    >> Share

  602. GARDNER L, Ratcliff J, Dong E, Katz A, et al
    A need for open public data standards and sharing in light of COVID-19.
    Lancet Infect Dis. 2020 Aug 10. pii: S1473-3099(20)30635.
    >> Share

  603. EPSTEIN JB, Chow K, Mathias R
    Dental procedure aerosols and COVID-19.
    Lancet Infect Dis. 2020 Aug 10. pii: S1473-3099(20)30636.
    >> Share

  604. KALK A, Schultz A
    SARS-CoV-2 epidemic in African countries-are we losing perspective?
    Lancet Infect Dis. 2020 Aug 7. pii: S1473-3099(20)30563.
    >> Share

  605. HEYWOOD AE, Macintyre CR
    Elimination of COVID-19: what would it look like and is it possible?
    Lancet Infect Dis. 2020 Aug 6. pii: S1473-3099(20)30633.
    >> Share

  606. ARORA RK, Joseph A, Van Wyk J, Rocco S, et al
    SeroTracker: a global SARS-CoV-2 seroprevalence dashboard.
    Lancet Infect Dis. 2020 Aug 4. pii: S1473-3099(20)30631.
    >> Share

  607. JOY M, Hobbs FDR, McGagh D, Akinyemi O, et al
    Excess mortality from COVID-19 in an English sentinel network population.
    Lancet Infect Dis. 2020 Aug 4. pii: S1473-3099(20)30632.
    >> Share

  608. IVERSEN K, Bundgaard H, Hasselbalch RB, Kristensen JH, et al
    Risk of COVID-19 in health-care workers in Denmark: an observational cohort study.
    Lancet Infect Dis. 2020 Aug 3. pii: S1473-3099(20)30589.
    >> Share

  609. KUCHARSKI AJ, Nilles EJ
    Using serological data to understand unobserved SARS-CoV-2 risk in health-care settings.
    Lancet Infect Dis. 2020 Aug 3. pii: S1473-3099(20)30579.
    >> Share

  610. BURKI T
    The indirect impact of COVID-19 on women.
    Lancet Infect Dis. 2020;20:904-905.
    >> Share

  611. JESUDASON T
    New WHO road map for NTD recovery post COVID-19.
    Lancet Infect Dis. 2020;20:902.
    >> Share

  612. KIRBY T
    Annelies Wilder-Smith.
    Lancet Infect Dis. 2020;20:907.
    >> Share

  613. BARBER S
    Death by racism.
    Lancet Infect Dis. 2020;20:903.
    >> Share

    July 2020
  614. DAWOOD FS, Ricks P, Njie GJ, Daugherty M, et al
    Observations of the global epidemiology of COVID-19 from the prepandemic period using web-based surveillance: a cross-sectional analysis.
    Lancet Infect Dis. 2020 Jul 29. pii: S1473-3099(20)30581.
    >> Share

  615. GRILLO F, Barisione E, Ball L, Mastracci L, et al
    Lung fibrosis: an undervalued finding in COVID-19 pathological series.
    Lancet Infect Dis. 2020 Jul 28. pii: S1473-3099(20)30582.
    >> Share

  616. PEELING RW, Boeras D, Wilder-Smith A, Sall A, et al
    Need for sustainable biobanking networks for COVID-19 and other diseases of epidemic potential.
    Lancet Infect Dis. 2020 Jul 24. pii: S1473-3099(20)30461.
    >> Share

  617. BIELICKI JA, Duval X, Gobat N, Goossens H, et al
    Monitoring approaches for health-care workers during the COVID-19 pandemic.
    Lancet Infect Dis. 2020 Jul 23. pii: S1473-3099(20)30458.
    >> Share

  618. THE LANCET INFECTIOUS DISEASES
    The COVID-19 infodemic.
    Lancet Infect Dis. 2020 Jul 17. pii: S1473-3099(20)30565.
    >> Share

  619. COOK M
    Potential factors linked to high COVID-19 death rates in British minority ethnic groups.
    Lancet Infect Dis. 2020 Jul 17. pii: S1473-3099(20)30583.
    >> Share

  620. PEELING RW, Wedderburn CJ, Garcia PJ, Boeras D, et al
    Serology testing in the COVID-19 pandemic response.
    Lancet Infect Dis. 2020 Jul 17. pii: S1473-3099(20)30517.
    >> Share

  621. EBERHARDT JN, Breuckmann NP, Eberhardt CS
    Challenges and issues of SARS-CoV-2 pool testing.
    Lancet Infect Dis. 2020 Jul 14. pii: S1473-3099(20)30467.
    >> Share

  622. BEHRMANN O, Spiegel M
    COVID-19: from rapid genome sequencing to fast decisions.
    Lancet Infect Dis. 2020 Jul 14. pii: S1473-3099(20)30580.
    >> Share

  623. LOHSE S, Pfuhl T, Berko-Gottel B, Gartner B, et al
    Challenges and issues of SARS-CoV-2 pool testing - Authors' reply.
    Lancet Infect Dis. 2020 Jul 14. pii: S1473-3099(20)30455.
    >> Share

  624. PEREZ-SAEZ J, Lauer SA, Kaiser L, Regard S, et al
    Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland.
    Lancet Infect Dis. 2020 Jul 14. pii: S1473-3099(20)30584.
    >> Share

  625. MISHRA B, Behera B, Mohanty M, Ravindra A, et al
    Challenges and issues of SARS-CoV-2 pool testing.
    Lancet Infect Dis. 2020 Jul 14. pii: S1473-3099(20)30463.
    >> Share

  626. MEREDITH LW, Hamilton WL, Warne B, Houldcroft CJ, et al
    Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance study.
    Lancet Infect Dis. 2020 Jul 14. pii: S1473-3099(20)30562.
    >> Share

  627. LEE J, Kim SY, Sung H, Lee SW, et al
    Challenges and issues of SARS-CoV-2 pool testing.
    Lancet Infect Dis. 2020 Jul 14. pii: S1473-3099(20)30516.
    >> Share

  628. MEI Q, Li J, Du R, Yuan X, et al
    Assessment of patients who tested positive for COVID-19 after recovery.
    Lancet Infect Dis. 2020 Jul 6. pii: S1473-3099(20)30433.
    >> Share

  629. GOLDMAN E
    Exaggerated risk of transmission of COVID-19 by fomites.
    Lancet Infect Dis. 2020 Jul 3. pii: S1473-3099(20)30561.
    >> Share

  630. HOXHA A, Wyndham-Thomas C, Klamer S, Dubourg D, et al
    Asymptomatic SARS-CoV-2 infection in Belgian long-term care facilities.
    Lancet Infect Dis. 2020 Jul 3. pii: S1473-3099(20)30560.
    >> Share

  631. PETERSEN E, Koopmans M, Go U, Hamer DH, et al
    Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics.
    Lancet Infect Dis. 2020 Jul 3. pii: S1473-3099(20)30484.
    >> Share

  632. SIKKEMA RS, Pas SD, Nieuwenhuijse DF, O'Toole A, et al
    COVID-19 in health-care workers in three hospitals in the south of the Netherlands: a cross-sectional study.
    Lancet Infect Dis. 2020 Jul 2. pii: S1473-3099(20)30527.
    >> Share

  633. BALAKRISHNAN VS
    COVID-19: Playing away the pandemic.
    Lancet Infect Dis. 2020;20:792.
    >> Share

  634. VENKATESAN P
    COVID-19 in Iran: round 2.
    Lancet Infect Dis. 2020;20:784.
    >> Share

  635. TRIUNFOL M
    High COVID-19 testing rate in Portugal.
    Lancet Infect Dis. 2020;20:783.
    >> Share

  636. BAGCCHI S
    Stigma during the COVID-19 pandemic.
    Lancet Infect Dis. 2020;20:782.
    >> Share

  637. BADR HS, Du H, Marshall M, Dong E, et al
    Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study.
    Lancet Infect Dis. 2020 Jul 1. pii: S1473-3099(20)30553.
    >> Share

  638. AZMAN AS, Luquero FJ
    From China: hope and lessons for COVID-19 control.
    Lancet Infect Dis. 2020;20:756-757.
    >> Share

  639. ZHANG J, Litvinova M, Wang W, Wang Y, et al
    Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study.
    Lancet Infect Dis. 2020;20:793-802.
    >> Share

  640. JIA Z, Lu Z
    Modelling COVID-19 transmission: from data to intervention.
    Lancet Infect Dis. 2020;20:757-758.
    >> Share

  641. NIEHUS R, De Salazar PM, Taylor AR, Lipsitch M, et al
    Using observational data to quantify bias of traveller-derived COVID-19 prevalence estimates in Wuhan, China.
    Lancet Infect Dis. 2020;20:803-808.
    >> Share

  642. AHMED H, Allaf M, Elghazaly H
    COVID-19 and medical education.
    Lancet Infect Dis. 2020;20:777-778.
    >> Share

  643. BAUD D, Nielsen-Saines K, Qi X, Musso D, et al
    Authors' reply.
    Lancet Infect Dis. 2020;20:775-776.
    >> Share

  644. BURKI T
    Global shortage of personal protective equipment.
    Lancet Infect Dis. 2020;20:785-786.
    >> Share


  645. Global outbreak research: harmony not hegemony.
    Lancet Infect Dis. 2020;20:770-772.
    >> Share

    June 2020
  646. DODD RH, Cvejic E, Bonner C, Pickles K, et al
    Willingness to vaccinate against COVID-19 in Australia.
    Lancet Infect Dis. 2020 Jun 30. pii: S1473-3099(20)30559.
    >> Share

  647. ABBAS M, Pittet D
    Surfing the COVID-19 scientific wave.
    Lancet Infect Dis. 2020 Jun 30. pii: S1473-3099(20)30558.
    >> Share

  648. SARDANELLI F, Cozzi A, Monfardini L, Bna C, et al
    Association of mediastinal lymphadenopathy with COVID-19 prognosis.
    Lancet Infect Dis. 2020 Jun 19. pii: S1473-3099(20)30521.
    >> Share

  649. HUBICHE T, Le Duff F, Chiaverini C, Giordanengo V, et al
    Negative SARS-CoV-2 PCR in patients with chilblain-like lesions.
    Lancet Infect Dis. 2020 Jun 18. pii: S1473-3099(20)30518.
    >> Share

  650. PITZER VE, Cohen T
    Household studies provide key insights on the transmission of, and susceptibility to, SARS-CoV-2.
    Lancet Infect Dis. 2020 Jun 17. pii: S1473-3099(20)30514.
    >> Share

  651. JING QL, Liu MJ, Zhang ZB, Fang LQ, et al
    Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study.
    Lancet Infect Dis. 2020 Jun 17. pii: S1473-3099(20)30471.
    >> Share

  652. AFRA TP, T MR, Bishnoi A, Hafi NB, et al
    Hydroxychloroquine use in COVID-19: what is the basis for baseline tests?
    Lancet Infect Dis. 2020 Jun 16. pii: S1473-3099(20)30472.
    >> Share

  653. MACINTYRE CR
    Case isolation, contact tracing, and physical distancing are pillars of COVID-19 pandemic control, not optional choices.
    Lancet Infect Dis. 2020 Jun 15. pii: S1473-3099(20)30512.
    >> Share

  654. KUCHARSKI AJ, Klepac P, Conlan AJK, Kissler SM, et al
    Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study.
    Lancet Infect Dis. 2020 Jun 15. pii: S1473-3099(20)30457.
    >> Share

  655. TEDDER RS, Semple MG
    Appropriate selection of convalescent plasma donors for COVID-19.
    Lancet Infect Dis. 2020 Jun 15. pii: S1473-3099(20)30470.
    >> Share

  656. NTOUMI F, Velavan TP
    COVID-19 in Africa: between hope and reality.
    Lancet Infect Dis. 2020 Jun 15. pii: S1473-3099(20)30465.
    >> Share

  657. COX RJ, Brokstad KA, Krammer F, Langeland N, et al
    Seroconversion in household members of COVID-19 outpatients.
    Lancet Infect Dis. 2020 Jun 15. pii: S1473-3099(20)30466.
    >> Share


  658. A minimal common outcome measure set for COVID-19 clinical research.
    Lancet Infect Dis. 2020 Jun 12. pii: S1473-3099(20)30483.
    >> Share

  659. OOI EE, Low JG
    Asymptomatic SARS-CoV-2 infection.
    Lancet Infect Dis. 2020 Jun 12. pii: S1473-3099(20)30460.
    >> Share

  660. TABATA S, Imai K, Kawano S, Ikeda M, et al
    Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis.
    Lancet Infect Dis. 2020 Jun 12. pii: S1473-3099(20)30482.
    >> Share

  661. HUNG IF, Cheng VC, Li X, Tam AR, et al
    SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series.
    Lancet Infect Dis. 2020 Jun 12. pii: S1473-3099(20)30364.
    >> Share

  662. THE LANCET INFECTIOUS DISEASES
    Political casualties of the COVID-19 pandemic.
    Lancet Infect Dis. 2020 Jun 11. pii: S1473-3099(20)30496.
    >> Share

  663. CARSANA L, Sonzogni A, Nasr A, Rossi RS, et al
    Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study.
    Lancet Infect Dis. 2020 Jun 8. pii: S1473-3099(20)30434.
    >> Share

  664. YI ES, Cecchini MJ, Bois MC
    Pathologists in pursuit of the COVID-19 culprit.
    Lancet Infect Dis. 2020 Jun 8. pii: S1473-3099(20)30449.
    >> Share

  665. MCDONALD ES
    COVID-19 and essential pregnant worker policies.
    Lancet Infect Dis. 2020 Jun 2. pii: S1473-3099(20)30446.
    >> Share

  666. EKTORP E
    Death threats after a trial on chloroquine for COVID-19.
    Lancet Infect Dis. 2020;20:661.
    >> Share

  667. NAKKAZI E
    Obstacles to COVID-19 control in east Africa.
    Lancet Infect Dis. 2020;20:660.
    >> Share

  668. HOLT E
    COVID-19 lockdown of Roma settlements in Slovakia.
    Lancet Infect Dis. 2020;20:659.
    >> Share

  669. KOO JR, Cook AR, Park M, Sun Y, et al
    Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study.
    Lancet Infect Dis. 2020;20:678-688.
    >> Share

  670. MOUSAVI SH, Shah J, Giang HTN, Al-Ahdal TMA, et al
    The first COVID-19 case in Afghanistan acquired from Iran.
    Lancet Infect Dis. 2020;20:657-658.
    >> Share

  671. LEWNARD JA, Lo NC
    Scientific and ethical basis for social-distancing interventions against COVID-19.
    Lancet Infect Dis. 2020;20:631-633.
    >> Share

  672. KELVIN AA, Halperin S
    COVID-19 in children: the link in the transmission chain.
    Lancet Infect Dis. 2020;20:633-634.
    >> Share

  673. RUAN S
    Likelihood of survival of coronavirus disease 2019.
    Lancet Infect Dis. 2020;20:630-631.
    >> Share

  674. THE LANCET INFECTIOUS DISEASES
    Riding the coronacoaster of uncertainty.
    Lancet Infect Dis. 2020;20:629.
    >> Share

  675. HUSSAINI SMQ
    Dearth of infectious diseases physicians as the USA faces a global pandemic.
    Lancet Infect Dis. 2020;20:648-649.
    >> Share

    May 2020
  676. JAMROZIK E, Selgelid MJ
    COVID-19 human challenge studies: ethical issues.
    Lancet Infect Dis. 2020 May 29. pii: S1473-3099(20)30438.
    >> Share

  677. OSORIO NS, Correia-Neves M
    Implication of SARS-CoV-2 evolution in the sensitivity of RT-qPCR diagnostic assays.
    Lancet Infect Dis. 2020 May 28. pii: S1473-3099(20)30435.
    >> Share

  678. WOOD SN, Wit EC, Fasiolo M, Green PJ, et al
    COVID-19 and the difficulty of inferring epidemiological parameters from clinical data.
    Lancet Infect Dis. 2020 May 28. pii: S1473-3099(20)30437.
    >> Share

  679. VERITY R, Okell L, Dorigatti I, Winskill P, et al
    COVID-19 and the difficulty of inferring epidemiological parameters from clinical data - Authors' reply.
    Lancet Infect Dis. 2020 May 28. pii: S1473-3099(20)30443.
    >> Share

  680. TILANGI P, Desai D, Khan A, Soneja M, et al
    Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach.
    Lancet Infect Dis. 2020 May 22. pii: S1473-3099(20)30430.
    >> Share


  681. A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation.
    Lancet Infect Dis. 2020 May 20. pii: S1473-3099(20)30426.
    >> Share

  682. BAUCH CT, Anand M
    COVID-19: when should quarantine be enforced?
    Lancet Infect Dis. 2020 May 20. pii: S1473-3099(20)30428.
    >> Share

  683. PEAK CM, Kahn R, Grad YH, Childs LM, et al
    Individual quarantine versus active monitoring of contacts for the mitigation of COVID-19: a modelling study.
    Lancet Infect Dis. 2020 May 20. pii: S1473-3099(20)30361.
    >> Share

  684. HAN MS, Byun JH, Cho Y, Rim JH, et al
    RT-PCR for SARS-CoV-2: quantitative versus qualitative.
    Lancet Infect Dis. 2020 May 20. pii: S1473-3099(20)30424.
    >> Share

  685. MEMISH ZA, Aljerian N, Ebrahim SH
    Tale of three seeding patterns of SARS-CoV-2 in Saudi Arabia.
    Lancet Infect Dis. 2020 May 19. pii: S1473-3099(20)30425.
    >> Share

  686. KHALIL A, Hill R, Ladhani S, Pattisson K, et al
    COVID-19 screening of health-care workers in a London maternity hospital.
    Lancet Infect Dis. 2020 May 18. pii: S1473-3099(20)30403.
    >> Share

  687. GUARNERI C, Rullo EV, Pavone P, Berretta M, et al
    Silent COVID-19: what your skin can reveal.
    Lancet Infect Dis. 2020 May 18. pii: S1473-3099(20)30402.
    >> Share

  688. BUONSENSO D, Parri N, De Rose C, Valentini P, et al
    Toward a clinically based classification of disease severity for paediatric COVID-19.
    Lancet Infect Dis. 2020 May 15. pii: S1473-3099(20)30396.
    >> Share

  689. DE LUSIGNAN S, Dorward J, Correa A, Jones N, et al
    Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study.
    Lancet Infect Dis. 2020 May 15. pii: S1473-3099(20)30371.
    >> Share

  690. BOHMER MM, Buchholz U, Corman VM, Hoch M, et al
    Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series.
    Lancet Infect Dis. 2020 May 15. pii: S1473-3099(20)30314.
    >> Share

  691. CHEN D, Tang F, Lu S, Song Q, et al
    Toward a clinically based classification of disease severity for paediatric COVID-19 - Authors' reply.
    Lancet Infect Dis. 2020 May 15. pii: S1473-3099(20)30397.
    >> Share

  692. SIMPSON CR, Thomas BD, Challen K, De Angelis D, et al
    The UK hibernated pandemic influenza research portfolio: triggered for COVID-19.
    Lancet Infect Dis. 2020 May 15. pii: S1473-3099(20)30398.
    >> Share

  693. RYBNIKER J, Fatkenheuer G
    Importance of precise data on SARS-CoV-2 transmission dynamics control.
    Lancet Infect Dis. 2020 May 15. pii: S1473-3099(20)30359.
    >> Share

  694. JORDAN RE, Adab P
    Who is most likely to be infected with SARS-CoV-2?
    Lancet Infect Dis. 2020 May 15. pii: S1473-3099(20)30395.
    >> Share

  695. WRIGHT DJM
    Prevention of the cytokine storm in COVID-19.
    Lancet Infect Dis. 2020 May 7. pii: S1473-3099(20)30376.
    >> Share

  696. LIPSITCH M, Perlman S, Waldor MK
    Testing COVID-19 therapies to prevent progression of mild disease.
    Lancet Infect Dis. 2020 May 6. pii: S1473-3099(20)30372.
    >> Share

  697. WELLS CR, Stearns JK, Lutumba P, Galvani AP, et al
    COVID-19 on the African continent.
    Lancet Infect Dis. 2020 May 6. pii: S1473-3099(20)30374.
    >> Share

  698. MBOPI-KEOU FX, Pondi JE, Sosso MA
    COVID-19 in Cameroon: a crucial equation to resolve.
    Lancet Infect Dis. 2020 May 6. pii: S1473-3099(20)30373.
    >> Share

  699. CHETTERJE P
    Gaps in India's preparedness for COVID-19 control.
    Lancet Infect Dis. 2020;20:544.
    >> Share

  700. RANSCOMBE P
    Rural areas at risk during COVID-19 pandemic.
    Lancet Infect Dis. 2020;20:545.
    >> Share

  701. THE LANCET INFECTIOUS DISEASES
    COVID-19: endgames.
    Lancet Infect Dis. 2020;20:511.
    >> Share

  702. BURKI T
    COVID-19 in Latin America.
    Lancet Infect Dis. 2020;20:547-548.
    >> Share

  703. TO KK, Tsang OT, Leung WS, Tam AR, et al
    Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.
    Lancet Infect Dis. 2020;20:565-574.
    >> Share

  704. CHEN Y, Li L
    SARS-CoV-2: virus dynamics and host response.
    Lancet Infect Dis. 2020;20:515-516.
    >> Share

  705. MCBRYDE E
    The value of early transmission dynamic studies in emerging infectious diseases.
    Lancet Infect Dis. 2020;20:512-513.
    >> Share

  706. SIMPSON S, Kaufmann MC, Glozman V, Chakrabarti A, et al
    Disease X: accelerating the development of medical countermeasures for the next pandemic.
    Lancet Infect Dis. 2020;20:e108-e115.
    >> Share

    April 2020
  707. LANG M, Som A, Mendoza DP, Flores EJ, et al
    Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT.
    Lancet Infect Dis. 2020 Apr 30. pii: S1473-3099(20)30367.
    >> Share

  708. ENDEMAN H, van der Zee P, van Genderen ME, van den Akker JPC, et al
    Progressive respiratory failure in COVID-19: a hypothesis.
    Lancet Infect Dis. 2020 Apr 29. pii: S1473-3099(20)30366.
    >> Share

  709. LOHSE S, Pfuhl T, Berko-Gottel B, Rissland J, et al
    Pooling of samples for testing for SARS-CoV-2 in asymptomatic people.
    Lancet Infect Dis. 2020 Apr 28. pii: S1473-3099(20)30362.
    >> Share

  710. SUN K, Viboud C
    Impact of contact tracing on SARS-CoV-2 transmission.
    Lancet Infect Dis. 2020 Apr 27. pii: S1473-3099(20)30357.
    >> Share

  711. NEGIDA A
    Estimation of COVID-19 burden in Egypt.
    Lancet Infect Dis. 2020 Apr 27. pii: S1473-3099(20)30329.
    >> Share

  712. SAHMOUD T
    Estimation of COVID-19 burden in Egypt.
    Lancet Infect Dis. 2020 Apr 27. pii: S1473-3099(20)30318.
    >> Share

  713. BI Q, Wu Y, Mei S, Ye C, et al
    Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study.
    Lancet Infect Dis. 2020 Apr 27. pii: S1473-3099(20)30287.
    >> Share

  714. HASSANY M, Abdel-Razek W, Asem N, AbdAllah M, et al
    Estimation of COVID-19 burden in Egypt.
    Lancet Infect Dis. 2020 Apr 27. pii: S1473-3099(20)30319.
    >> Share

  715. ELMELEEGY K
    Estimation of COVID-19 burden in Egypt.
    Lancet Infect Dis. 2020 Apr 27. pii: S1473-3099(20)30321.
    >> Share

  716. TUITE AR, Ng V, Rees E, Fisman D, et al
    Estimation of COVID-19 burden in Egypt - Authors' reply.
    Lancet Infect Dis. 2020 Apr 27. pii: S1473-3099(20)30326.
    >> Share

  717. YU N, Li W, Kang Q, Zeng W, et al
    No SARS-CoV-2 detected in amniotic fluid in mid-pregnancy.
    Lancet Infect Dis. 2020 Apr 22. pii: S1473-3099(20)30320.
    >> Share

  718. WINTER AK, Hegde ST
    The important role of serology for COVID-19 control.
    Lancet Infect Dis. 2020 Apr 21. pii: S1473-3099(20)30322.
    >> Share

  719. VALETTE X, du Cheyron D, Goursaud S
    Mediastinal lymphadenopathy in patients with severe COVID-19.
    Lancet Infect Dis. 2020 Apr 21. pii: S1473-3099(20)30310.
    >> Share

  720. YONG SEF, Anderson DE, Wei WE, Pang J, et al
    Connecting clusters of COVID-19: an epidemiological and serological investigation.
    Lancet Infect Dis. 2020 Apr 21. pii: S1473-3099(20)30273.
    >> Share

  721. HARGREAVES S, Zenner D, Wickramage K, Deal A, et al
    Targeting COVID-19 interventions towards migrants in humanitarian settings.
    Lancet Infect Dis. 2020 Apr 21. pii: S1473-3099(20)30292.
    >> Share

  722. WELLS CR, Fitzpatrick MC, Sah P, Shoukat A, et al
    Projecting the demand for ventilators at the peak of the COVID-19 outbreak in the USA.
    Lancet Infect Dis. 2020 Apr 20. pii: S1473-3099(20)30315.
    >> Share

  723. GABORIT BJ, Bergmann JF, Mussini C, Arribas JR, et al
    Plea for multitargeted interventions for severe COVID-19.
    Lancet Infect Dis. 2020 Apr 20. pii: S1473-3099(20)30312.
    >> Share

  724. MODJARRAD K, Kim JH
    Two Middle East respiratory syndrome vaccines: first step for other coronavirus vaccines?
    Lancet Infect Dis. 2020 Apr 20. pii: S1473-3099(20)30317.
    >> Share

  725. FOLEGATTI PM, Bittaye M, Flaxman A, Lopez FR, et al
    Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.
    Lancet Infect Dis. 2020 Apr 20. pii: S1473-3099(20)30160.
    >> Share

  726. KOCH T, Dahlke C, Fathi A, Kupke A, et al
    Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.
    Lancet Infect Dis. 2020 Apr 20. pii: S1473-3099(20)30248.
    >> Share

  727. NELSON R
    COVID-19 disrupts vaccine delivery.
    Lancet Infect Dis. 2020 Apr 17. pii: S1473-3099(20)30304.
    >> Share

  728. GLYNN JR
    Protecting workers aged 60-69 years from COVID-19.
    Lancet Infect Dis. 2020 Apr 16. pii: S1473-3099(20)30311.
    >> Share

  729. BENEZIT F, Le Turnier P, Declerck C, Paille C, et al
    Utility of hyposmia and hypogeusia for the diagnosis of COVID-19.
    Lancet Infect Dis. 2020 Apr 15. pii: S1473-3099(20)30297.
    >> Share

  730. MEYER JP, Franco-Paredes C, Parmar P, Yasin F, et al
    COVID-19 and the coming epidemic in US immigration detention centres.
    Lancet Infect Dis. 2020 Apr 15. pii: S1473-3099(20)30295.
    >> Share

  731. XYDAKIS MS, Dehgani-Mobaraki P, Holbrook EH, Geisthoff UW, et al
    Smell and taste dysfunction in patients with COVID-19.
    Lancet Infect Dis. 2020 Apr 15. pii: S1473-3099(20)30293.
    >> Share

  732. MARTINEZ-PORTILLA RJ, Gonce A, Hawkins-Villarreal A, Figueras F, et al
    A Spanish-translated clinical algorithm for management of suspected SARS-CoV-2 infection in pregnant women.
    Lancet Infect Dis. 2020 Apr 9. pii: S1473-3099(20)30285.
    >> Share

  733. KUCHARSKI AJ, Eggo RM
    Invisible spread of SARS-CoV-2 - Authors' reply.
    Lancet Infect Dis. 2020 Apr 7. pii: S1473-3099(20)30275.
    >> Share

  734. ZHANG W, Qian BY
    Making decisions to mitigate COVID-19 with limited knowledge.
    Lancet Infect Dis. 2020 Apr 7. pii: S1473-3099(20)30280.
    >> Share

  735. XIONG N, Wang T, Lin Z
    Invisible spread of SARS-CoV-2.
    Lancet Infect Dis. 2020 Apr 7. pii: S1473-3099(20)30263.
    >> Share

  736. RICHARDSON PJ, Corbellino M, Stebbing J
    Baricitinib for COVID-19: a suitable treatment? - Authors' reply.
    Lancet Infect Dis. 2020 Apr 3. pii: S1473-3099(20)30270.
    >> Share

  737. FAVALLI EG, Biggioggero M, Maioli G, Caporali R, et al
    Baricitinib for COVID-19: a suitable treatment?
    Lancet Infect Dis. 2020 Apr 3. pii: S1473-3099(20)30262.
    >> Share

  738. DEVI S
    US public health budget cuts in the face of COVID-19.
    Lancet Infect Dis. 2020;20:415.
    >> Share

    March 2020
  739. POLAND GA
    SARS-CoV-2: a time for clear and immediate action.
    Lancet Infect Dis. 2020 Mar 31. pii: S1473-3099(20)30250.
    >> Share

  740. SPYCHALSKI P, Blazynska-Spychalska A, Kobiela J
    Estimating case fatality rates of COVID-19.
    Lancet Infect Dis. 2020 Mar 31. pii: S1473-3099(20)30246.
    >> Share

  741. KIM DD, Goel A
    Estimating case fatality rates of COVID-19.
    Lancet Infect Dis. 2020 Mar 31. pii: S1473-3099(20)30234.
    >> Share

  742. LIPSITCH M
    Estimating case fatality rates of COVID-19.
    Lancet Infect Dis. 2020 Mar 31. pii: S1473-3099(20)30245.
    >> Share

  743. VERITY R, Okell LC, Dorigatti I, Winskill P, et al
    Estimates of the severity of coronavirus disease 2019: a model-based analysis.
    Lancet Infect Dis. 2020 Mar 30. pii: S1473-3099(20)30243.
    >> Share

  744. RAJGOR DD, Lee MH, Archuleta S, Bagdasarian N, et al
    The many estimates of the COVID-19 case fatality rate.
    Lancet Infect Dis. 2020 Mar 27. pii: S1473-3099(20)30244.
    >> Share

  745. LESCURE FX, Bouadma L, Nguyen D, Parisey M, et al
    Clinical and virological data of the first cases of COVID-19 in Europe: a case series.
    Lancet Infect Dis. 2020 Mar 27. pii: S1473-3099(20)30200.
    >> Share

  746. JOYNT GM, Wu WK
    Understanding COVID-19: what does viral RNA load really mean?
    Lancet Infect Dis. 2020 Mar 27. pii: S1473-3099(20)30237.
    >> Share

  747. HUANG Y, Cheng W, Zhao N, Qu H, et al
    CT screening for early diagnosis of SARS-CoV-2 infection.
    Lancet Infect Dis. 2020 Mar 26. pii: S1473-3099(20)30241.
    >> Share

  748. SHI H, Han X, Cao Y, Alwalid O, et al
    CT screening for early diagnosis of SARS-CoV-2 infection - Authors' reply.
    Lancet Infect Dis. 2020 Mar 26. pii: S1473-3099(20)30247.
    >> Share

  749. TUITE AR, Ng V, Rees E, Fisman D, et al
    Estimation of the COVID-19 burden in Egypt through exported case detection.
    Lancet Infect Dis. 2020 Mar 26. pii: S1473-3099(20)30233.
    >> Share

  750. QIU H, Wu J, Hong L, Luo Y, et al
    Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study.
    Lancet Infect Dis. 2020 Mar 25. pii: S1473-3099(20)30198.
    >> Share

  751. LUO Y, Yin K
    Management of pregnant women infected with COVID-19.
    Lancet Infect Dis. 2020 Mar 24. pii: S1473-3099(20)30191.
    >> Share

  752. YU N, Li W, Kang Q, Xiong Z, et al
    Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study.
    Lancet Infect Dis. 2020 Mar 24. pii: S1473-3099(20)30176.
    >> Share

  753. TUITE AR, Ng V, Rees E, Fisman D, et al
    Estimation of COVID-19 outbreak size in Italy.
    Lancet Infect Dis. 2020 Mar 19. pii: S1473-3099(20)30227.
    >> Share

  754. LIU Y, Yan LM, Wan L, Xiang TX, et al
    Viral dynamics in mild and severe cases of COVID-19.
    Lancet Infect Dis. 2020 Mar 19. pii: S1473-3099(20)30232.
    >> Share

  755. SCHMID MB, Fontijn J, Ochsenbein-Kolble N, Berger C, et al
    COVID-19 in pregnant women.
    Lancet Infect Dis. 2020 Mar 17. pii: S1473-3099(20)30175.
    >> Share

  756. BAUD D, Giannoni E, Pomar L, Qi X, et al
    COVID-19 in pregnant women - Authors' reply.
    Lancet Infect Dis. 2020 Mar 17. pii: S1473-3099(20)30192.
    >> Share

  757. THE LANCET INFECTIOUS DISEASES
    COVID-19, a pandemic or not?
    Lancet Infect Dis. 2020 Mar 13. pii: S1473-3099(20)30180.
    >> Share

  758. BAUD D, Qi X, Nielsen-Saines K, Musso D, et al
    Real estimates of mortality following COVID-19 infection.
    Lancet Infect Dis. 2020 Mar 12. pii: S1473-3099(20)30195.
    >> Share

  759. HAN H, Luo Q, Mo F, Long L, et al
    SARS-CoV-2 RNA more readily detected in induced sputum than in throat swabs of convalescent COVID-19 patients.
    Lancet Infect Dis. 2020 Mar 12. pii: S1473-3099(20)30174.
    >> Share

  760. KUCHARSKI AJ, Russell TW, Diamond C, Liu Y, et al
    Early dynamics of transmission and control of COVID-19: a mathematical modelling study.
    Lancet Infect Dis. 2020 Mar 11. pii: S1473-3099(20)30144.
    >> Share

  761. ZHOU C, Gao C, Xie Y, Xu M, et al
    COVID-19 with spontaneous pneumomediastinum.
    Lancet Infect Dis. 2020 Mar 9. pii: S1473-3099(20)30156.
    >> Share

  762. WILDER-SMITH A, Chiew CJ, Lee VJ
    Can we contain the COVID-19 outbreak with the same measures as for SARS?
    Lancet Infect Dis. 2020 Mar 5. pii: S1473-3099(20)30129.
    >> Share

  763. XIAO Y, Torok ME
    Taking the right measures to control COVID-19.
    Lancet Infect Dis. 2020 Mar 5. pii: S1473-3099(20)30152.
    >> Share

  764. YAN G, Lee CK, Lam LTM, Yan B, et al
    Covert COVID-19 and false-positive dengue serology in Singapore.
    Lancet Infect Dis. 2020 Mar 4. pii: S1473-3099(20)30158.
    >> Share

  765. THANH HN, Van TN, Thu HNT, Van BN, et al
    Outbreak investigation for COVID-19 in northern Vietnam.
    Lancet Infect Dis. 2020 Mar 4. pii: S1473-3099(20)30159.
    >> Share

  766. FAVRE G, Pomar L, Qi X, Nielsen-Saines K, et al
    Guidelines for pregnant women with suspected SARS-CoV-2 infection.
    Lancet Infect Dis. 2020 Mar 3. pii: S1473-3099(20)30157.
    >> Share

  767. THE LANCET INFECTIOUS DISEASES
    Challenges of coronavirus disease 2019.
    Lancet Infect Dis. 2020;20:261.
    >> Share

  768. BURKI T
    Outbreak of coronavirus disease 2019.
    Lancet Infect Dis. 2020;20:292-293.
    >> Share

  769. BASTOLA A, Sah R, Rodriguez-Morales AJ, Lal BK, et al
    The first 2019 novel coronavirus case in Nepal.
    Lancet Infect Dis. 2020;20:279-280.
    >> Share

  770. LI J, Li JJ, Xie X, Cai X, et al
    Game consumption and the 2019 novel coronavirus.
    Lancet Infect Dis. 2020;20:275-276.
    >> Share

    February 2020
  771. HUANG R, Xia J, Chen Y, Shan C, et al
    A family cluster of SARS-CoV-2 infection involving 11 patients in Nanjing, China.
    Lancet Infect Dis. 2020 Feb 28. pii: S1473-3099(20)30147.
    >> Share

  772. CHEN L, Xiong J, Bao L, Shi Y, et al
    Convalescent plasma as a potential therapy for COVID-19.
    Lancet Infect Dis. 2020 Feb 27. pii: S1473-3099(20)30141.
    >> Share

  773. STEBBING J, Phelan A, Griffin I, Tucker C, et al
    COVID-19: combining antiviral and anti-inflammatory treatments.
    Lancet Infect Dis. 2020 Feb 27. pii: S1473-3099(20)30132.
    >> Share

  774. LEE EYP, Ng MY, Khong PL
    COVID-19 pneumonia: what has CT taught us?
    Lancet Infect Dis. 2020 Feb 24. pii: S1473-3099(20)30134.
    >> Share

  775. PAN Y, Zhang D, Yang P, Poon LLM, et al
    Viral load of SARS-CoV-2 in clinical samples.
    Lancet Infect Dis. 2020 Feb 24. pii: S1473-3099(20)30113.
    >> Share

  776. SHI H, Han X, Jiang N, Cao Y, et al
    Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study.
    Lancet Infect Dis. 2020 Feb 24. pii: S1473-3099(20)30086.
    >> Share

  777. PAN X, Chen D, Xia Y, Wu X, et al
    Asymptomatic cases in a family cluster with SARS-CoV-2 infection.
    Lancet Infect Dis. 2020 Feb 19. pii: S1473-3099(20)30114.
    >> Share

  778. XU B, Kraemer MUG
    Open access epidemiological data from the COVID-19 outbreak.
    Lancet Infect Dis. 2020 Feb 19. pii: S1473-3099(20)30119.
    >> Share

  779. DONG E, Du H, Gardner L
    An interactive web-based dashboard to track COVID-19 in real time.
    Lancet Infect Dis. 2020 Feb 19. pii: S1473-3099(20)30120.
    >> Share

  780. CHEN X, Tian J, Li G, Li G, et al
    Initiation of a new infection control system for the COVID-19 outbreak.
    Lancet Infect Dis. 2020 Feb 18. pii: S1473-3099(20)30110.
    >> Share

  781. VAN CUONG L, Giang HTN, Linh LK, Shah J, et al
    The first Vietnamese case of COVID-19 acquired from China.
    Lancet Infect Dis. 2020 Feb 18. pii: S1473-3099(20)30111.
    >> Share

  782. THOMPSON R
    Pandemic potential of 2019-nCoV.
    Lancet Infect Dis. 2020 Feb 7. pii: S1473-3099(20)30068.
    >> Share

  783. BAGCCHI S
    Mysterious pneumonia in China.
    Lancet Infect Dis. 2020;20:173.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016